

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

A Phase II double-blind multi-center, placebo-controlled trial, to assess the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP) – the SESAM study protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-084614
Article Type:	Protocol
Date Submitted by the Author:	23-Jan-2024
Complete List of Authors:	Luu, Maxime; Centre Hospitalier Universitaire de Dijon, Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD) Vabres, Pierre; Centre référence MAGEC, Dermatology; St John's Institute of Dermatology, Espitalier, Aurélie; Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Maurer, Agnès; Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Garde, Aurore; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Racine, Caroline; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Racine, Caroline; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Carpentier, Maud; Centre Hospitalier Universitaire de Dijon, Département de Radiologie et Imagerie Diagnostique et Thérapeutique Loffroy, Romaric; Centre Hospitalier Universitaire de Dijon, Département de Radiologie et Imagerie Diagnostique et Thérapeutique Hadouiri, Nawale; Centre Hospitalier Universitaire de Dijon, Département of Médecine Physique et de Réadaptation Boddaert, Nathalie; Hôpital Universitaire Necker-Enfants Malades, INSERM UMR-1163 Institut Imagine; Hôpital Universitaire Necker-Enfants Malades, Département de Radiologie Pédiatrique Curie, Aurore; Hospices Civils de Lyon, Centre de référence Déficience Intellectuelle de causes rares, Service de neuropédiatrie, Hôpital Femme Mère Enfant Guibaud, Laure

	Pharmacologie périnatale, pédiatrique et adulte (site HEGP), Recherche Clinique Entrepôts de Données et Pharmacologie, GHU Paris. Université Paris Cité Charligny, Julie; Centre Hospitalier Universitaire Dijon Bourgogne, Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432 Kuentz, Paul; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Besancon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI Canaud, Guillaume; Assistance Publique - Hopitaux de Paris, INSERM UMR-1163 Institut Imagine, Hôpital Necker-Enfants Malades; Université Paris Cité, INSERM U1151, Unité de médecine translationnelle et thérapies ciblées, Hôpital Necker-Enfants Malades Bahi-Buisson, Nadia; Assistance Publique - Hopitaux de Paris, Département de Radiologie Pédiatrique, Hôpital Necker-Enfants Malades; Assistance Publique - Hopitaux de Paris, Service de Neurologie Pédiatrique, DMU MICADO, Hôpital Necker Enfants Malades Fleck, Camille; Centre Hospitalier Universitaire Dijon Bourgogne, Direction de la Recherche Clinique Cransac, Amelie; Centre Hospitalier Universitaire Dijon Bourgogne, Département de Pharmacie; Université de Bourgogne, INSERM LNC- UMR1231 Bardou, Marc; Centre Hospitalier Universitaire Dijon Bourgogne, Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD) Faivre, Laurence; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Diion Rourgogne, Centre de Piaresité de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de
	Dijon Bourgogne, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD
Keywords:	Developmental neurology & neurodisability < PAEDIATRICS, Clinical trials < THERAPEUTICS, Paediatric clinical genetics & dysmorphology < GENETICS, Neurogenetics < NEUROLOGY

SCHOLARONE[™] Manuscripts

BMJ Open

1	A Phase II double-blind multi-center, placebo-controlled trial, to assess the efficacy and
2	safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary
3	malformation Polymicrogyria syndrome (MCAP) – the SESAM study protocol
4	Maxime Luu ^{1,2} , Pierre Vabres ³ , Aurélie Espitalier ⁴ , Agnès Maurer ⁴ , Aurore Garde ^{2,4} , Caroline
5	Racine ^{2,4} , Maud Carpentier ⁵ , Adélaide Rega ⁶ , Romaric Loffroy ⁶ , Nawale Hadouiri ⁷ , Nathalie
6	Boddaert ^{8,9} , Aurore Curie ¹⁰ , Laurent Guibaud ¹¹ , Mouna Chebbi ¹² , Paul Kuentz ^{2,13} , Julie
7	Charligny ¹ , Guillaume Canaud ^{8,14} , Nadia Bahi-Buisson ^{9, 15} , Camille Fleck ⁵ , Amélie Cransac ^{16,17} ,
8	Marc Bardou ^{1,2} ⁺ and Laurence Faivre ^{2,4} ⁺ for the SESAM study group
9	
10	Author Affiliations
10	Author Anniations
11	¹ Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432, Centre
12	Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France
13	² INSERM UMR1231 Génétique des Anomalies du Développement (GAD), Université de
14	Bourgogne, Dijon, Bourgogne, France
15	³ Centre référence MAGEC, Dijon, France.
16	⁴ Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU
17	TRANSLAD, Centre Hospitalier Universitaire de Dijon, Dijon, France
18	⁵ Direction de la Recherche Clinique, Centre Hospitalier Universitaire de Dijon, Dijon,
19	Bourgogne, France
20	⁶ Département de Radiologie et Imagerie Diagnostique et Thérapeutique, Centre Hospitalier
21	Universitaire de Dijon, Dijon, Bourgogne, France
22	⁷ Département of Médecine Physique et de Réadaptation, Centre Hospitalier Universitaire de
23	Dijon, Dijon, Bourgogne, France

BMJ Open

24	⁸ INSERM UMR-1163 Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
25	⁹ Département de Radiologie Pédiatrique, Hôpital Necker-Enfants Malades, AP-HP, Paris,
26	France.
27	¹⁰ Centre de référence Déficience Intellectuelle de causes rares, Service de neuropédiatrie,
28	Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.
29	¹¹ Service d'Imagerie Pédiatrique, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron,
30	France.
31	¹² Service de Pharmacologie périnatale, pédiatrique et adulte (site HEGP), Recherche Clinique
32	Entrepôts de Données et Pharmacologie, GHU Paris.Centre - Université Paris Cité, Assistance
33	Publique Hôpitaux de Paris (APHP)
34	¹³ Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, CHU Besançon,
35	Besançon, France
36	¹⁴ INSERM U1151, Unité de médecine translationnelle et thérapies ciblées, Hôpital Necker-
37	Enfants Malades, Université Paris Cité, AP-HP, Paris, France.
38	¹⁵ Service de Neurologie Pédiatrique, DMU MICADO, APHP, Hôpital Necker Enfants Malades,
39	75015 Paris, France.
40	¹⁶ Département de Pharmacie, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne,
41	France
42	¹⁷ INSERM LNC-UMR1231, Université de Bourgogne, Dijon, France
43	
44	Corresponding author:
45	Maxime LUU
46	maxime.luu@chu-dijon.fr;
47	Tel.: (+ 33 380 295 892)
	 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47

2 3	48
4 5	
6 7	49
8	50
9 10	
11 12	51
12	
14 15	
16	
17 18	
19	
20 21	
22	
23 24	
25 26	
26 27	
28 20	
30	
31 32	
33	
34 35	
36	
37 38	
39	
40 41	
42	
43 44	
45 46	
40 47	
48 49	
50	
51 52	
53	
54 55	
56	
57 58	
59	

1

48 Name and contact information for the trial sponsor:

49 Maud CARPENTIER

50 maud.carpentier@chu-dijon.fr

for beet teries only

53

Abstract:

Introduction

1 2

_ ז	
1	
-	
5	
6	
7	
8	
9	
10	
11	
12	
13	
11	
14	
15	
10	
17	
18	
19	
20	
21	
22	
23	
24	
25	
25	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
27	
27	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
т/ ЛО	
40	
49 50	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	
29	
bυ	

54	The MCAP syndrome (Megalencephaly Capillary malformation Polymicrogyria) results from
55	mosaic gain-of-function PIK3CA variants. Main clinical features are macrocephaly, somatic
56	overgrowth, neurodevelopmental delay, and brain anomalies. Alpelisib (Vijoice®) is a recently
57	FDA-approved PI3K α -specific inhibitor for patients with PIK3CA-related overgrowth spectrum
58	(PROS). During its development, in patients with MCAP subgroup of PROS, there was no
59	specific, standardised evaluation of the effect on neuro-cognitive functioning. Moreover, it
60	remains unknown if the molecule crosses the blood-brain barrier. Our objective is to evaluate
61	the efficacy of a 24-month treatment with alpelisib on adaptive behaviour in patients with
62	MCAP syndrome.

63 Methods and Analysis

SESAM is an industry-sponsored two periods multi-centre French academic phase II trial, with 64 a 6 months double-blind, placebo-controlled period followed by open label period. Primary 65 endpoint is a \geq 4 points improvement in the Vineland II Adaptive Behavior Scale (VABS), 24 66 months after treatment initiation. Secondary objectives are safety, VABS improvement at 6 67 68 months, impact on quality of life, epilepsy and hypotonia. Twenty patients aged 2 to 40 years old, with a MCAP diagnosis and neurodevelopmental disorders of various degrees, will be 69 70 followed monthly in local centres, centrally assessed (clinical, biological, neuropsychological and functional evaluation) at baseline and every 6 months. Patients will be evaluated by 71 volumetric MRI at baseline and at 24 months. An optional lumbar puncture will be performed 72 73 to investigate blood-brain barrier crossing. Inclusions are expected to be completed by March 74 2024, with the end of follow-up in September 2026.

BMJ Open

- Given the efficacy of alpelisib in patients with PROS, if the drug crosses the blood-brain barrier,
- we can expect a clinical benefit for patients with neurocognitive disorders.

Ethics and dissemination

- Ethical approval was given by CPP Sud-Ouest et Outre-Mer I (reference: 2022-500197-34-01).
- Findings from this study will be disseminated via publication, reports and conference ,ClinicalTrials.gc
- presentations.
- Trial registration Number (ClinicalTrials.gov)
- NCT05577754

BMJ Open

1		
2		
3 4	83	
5		
6	84	Keywords:
7		
8	85	Neurodevelopmental disorders, alpelisib, therapeutic trial, PIK3CA, MCAP
9 10		
11	86	
12		
13	87	Word count: 3822 words
14		
15 16	88	
17		
18	89	Strengths and limitations of this study:
19		
20	90	• The SESAM trial is the first evaluation of alpelisib dedicated in patients with MCAP
21 22		
23	91	using neurocognitive endpoints.
24		
25	92	• The passage of alpelisib through the blood-brain barrier will be evaluated in the SESAM
26 27		
27 28	93	trial.
29		
30	94	• The two-period design (double blind placebo-controlled period followed by open-label
31		
32 33	95	period) has been chosen to comply with the best quality methodological standards.
34		
35	96	• Heterogeneity in patient's clinical presentation represents a challenge in the
36		5 , 1 1 1 5
37	97	interpretation of the results.
20 39		
40	98	• No international consensus exists on the scales to be used in clinical trials in patients
41		
42	99	with neurocognitive disorders.
43 44	00	
44 45	100	
46	200	
47		
48		
49 50		
51		
52		
53		
54 55		
56		
57		
58		
59 60		
00		

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

101 INTRODUCTION

Segmental overgrowth disorders (SODs) are rare conditions usually characterized by abnormal and asymetric growth of some parts of the body. This excessive tissue growth is caused by an overactivation of the cell proliferation mechanism. Mosaic activating variants in the $p110\alpha$ catalytic subunit of phosphatidylinositol-3 kinase (PI3K; encoded by the PIK3CA gene) have been identified in a subset of SODs. The PI3K-AKT-mTOR is a critical signalling pathway in regulating proliferation, survival and cell growth. Activating variants in PIK3CA lead to increased PI3K-AKT-mTORC1 axis activation, which in turn promotes excessive growth in affected tissues (1-6).

The PIK3CA-related overgrowth spectrum (PROS) is a congenital condition with progressively asymmetric overgrowth which can begin in the antenatal period. This disease is wide-ranging, and depends upon the timing of the founder mutation in embryogenesis (6-9). Depending on the clinical presentation (segmental body overgrowth or brain disorder), three main disease subgroups can be distinguished: the CLOVES syndrome (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/Skeletal/Spinal anomalies), the Klippel-Trenaunay syndrome and the MCAP syndrome (Megalencephaly Capillary malformation Polymicrogyria). CLOVES clinical presentation ranges from isolated digit enlargement to extensive overgrowth of limbs, thorax/abdomen and/or face. It may be accompanied by vascular or lymphatic malformations, epidermal nevi and spinal anomalies. Associated morbidity can be highly variable, but can include functional impairment, debilitating haemorrhages and thromboses, and, in some cases, can be lethal. For patients with Klippel-Trenaunay syndrome, vascular malformations are often in the foreground, associated with soft tissue and bone hypertrophy, and involve one limb, most often the lower limb. MCAP is

Page 9 of 35

BMJ Open

characterized by megalencephaly (large head), capillary malformation of the skin (middle face, limbs and trunk), abnormalities of the extremities and possible abnormalities of the brain structure (Chiari malformation, hydrocephalus, polymicrogyria) (9, 10). Megalencephaly is present at birth, and the brain continues to develop gradually during the first postnatal years with a relative stabilization with age, although remaining larger than normal. MCAP patients may experience impaired cognition, hypotonia, variable intellectual deficiency and seizures. Abnormalities of the brain structure may be present (hydrophalus, Chiari malformation and polymicrogyria in particular). Asymmetry of some body parts may also exist, as well as skin manifestations. Cardiac and genitourinary abnormalities have been reported in rare cases. The current diagnosis is established through a clinical evaluation and genetic testing on the affected tissues. In rare cases, the PIK3CA variant is present in all cells and not at a mosaic state. Magnetic resonance imaging (MRI) is used to identify and monitor brain abnormalities. The French National Protocol for Diagnosis and Care for MCAP syndrome (11) and an international expert consensus statement for standardizing care for individuals with PIK3CA-related disorders have been published (12). As patients may be misdiagnosed, the true prevalence of the disease is not well known. But in France, in 2021, more than 60 MCAP patients had already been genotyped. Variability in the degree of neurocognitive manifestations is considerable, ranging from mild learning disabilities to profound intellectual disability, in some cases associated with epilepsy (10).

143 The natural history of PROS shows that most of the overgrowth progression occurs during 144 early childhood, emphasizing the need to assess the potential benefit of early treatment in 145 paediatric patients with PROS. It could avert associated complications and/or surgery by 146 decreasing disease progression at this active stage.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Interestingly, drug treatments that specifically inhibit the p110 α catalytic subunit of PI3K have been developed in oncology in case of tumors with PIK3CA gain-of-function variants. Alpelisib (Vijoice[®], Novartis Pharmaceutical) have been authorized in metastatic breast cancer (13, 14), and has therefore been investigated through drug repurposing in PROS, in a case series of 19 French patients under a compassionate approach, including 2 with MCAP (15). After encouraging results in safety and efficacy, Novartis Pharmaceutical started the EPIK program. The EPIK-P1 (NCT04285723) is a real-world study for demonstrating clinical benefit in people with PROS, and EPIK-P3 (NCT04980833) a phase II study to assess long-term safety and efficacy of alpelisib in people with PROS who participated in EPIK-P1. The ongoing international prospective phase II double-blind, randomized, placebo-controlled study clinical trial (EPIK-P2, NCT04589650), is assessing efficacy, safety and pharmacokinetics of alpelisib in pediatric and adult patients with PROS. Positive preliminary results from EPIK-P1 led the FDA to grant early April 2022, an accelerated approval for alpelisib (Vijoice®) in PROS, including MCAP, for patients of 2 years of age and over, based on the efficacy (defined as a \geq 20% reduction from baseline in the sum of measurable target lesion volume) observed in 37 patients from EPIK-P1 after 6 months of treatment (16). However, these therapeutic studies preferentially targeted patients with CLOVES or Klippel-Trenaunay syndromes, and endpoints were not designed to assess neurocognitive improvement. Current data on alpelisib efficacy and safety in MCAP patients solely comes from compassionate use, which fails to demonstrate a clear benefit of the treatment on neurocognitive symptoms (15, 17). There is even no proof that alpelisib crosses the blood-brain barrier.

To assess the clinical benefit of Alpelisb in MCAP patients, it was necessary to construct a clinical trial evaluating specifically neurocognitive functions. Based on the clinical and radiological evaluation of 33 French patients with MCAP syndrome (10), we designed the

BMJ Open

SESAM study to demonstrate the safety and efficacy of alpelisib in these patients, and to assess its passage across the blood-brain barrier.

METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES

Study Setting

This study is promoted, partly funded, and coordinated by Dijon Bourgogne University Hospital. Drug supply and part of funding was supported by Novartis Pharmaceutical. It includes pediatric and adult patients covered by national health insurance. To minimize the logistic burden for the patients, inclusion and safety visits are performed in their local hospitals (9 sites in total). Two evaluating sites (Dijon Bourgogne University Hospital and Paris Necker Hospital) are in charge of the baseline and assessment visits.

Study design, participant, randomisation

Study design. The SESAM trial is a two-period multi-center Phase II trial, with 6 months double-blind, placebo-controlled period followed by an open label period (Figure 1). Patients and their legal representative are given by the investigator a consent form adapted to their age and ID severity. A separate and optional consent for lumbar puncture is also proposed. After validation of the screening exams at the inclusion visit, patients are randomized to take alpelisib (250mg/day for adults or 50mg/day for children) or placebo during 6 months, with a 1:1 ratio. A first evaluation will be performed at 6 months (secondary objective 1) to determine the response status and patients will be unblinded once the evaluation is done. Patients completing the double-blind phase will then be entered in an open-label phase as follows: patients on placebo will switch to alpelisib (250mg/day for adults or 50mg/day for

BMJ Open

> children), responders to alpelisib will continue alpelisib at same dose during 18 months, and non-responders will have their dose increased (300mg/day for adults, 125mg/day for children \geq 6 years old only). Dose increase is not permitted for children aged 5 years and below. Non-responders are patients who did not experience sufficient clinical benefit (based on overall clinical response assessed by the investigator) and with no safety/tolerability concerns which may preclude from treatment continuation at higher dose level. Patients will undergo additional evaluation visits every 6 months, and a final evaluation visit after 24 months of alpelisib treatment (main objective). Patients will undergo a main evaluation visit with clinical, biological, functional and neurocognitive exams every 6 months. Safety monitoring will be assured on a monthly basis. The schedule and content of the visits are detailed in supplemental material.

Participants. Patients aged 2-40 years, with documented evidence of postzygotic or constitutional variant(s) in PIK3CA and a diagnosis of MCAP with a neurocognitive disorder (from specific learning disorder to severe intellectual disability) at the time of consent could be included. The main exclusion criteria are related to contra-indications to alpelisib treatment such as history of pancreatitis, diabetes, or pneumonitis.

Randomisation. Randomisation will be performed by the site staff using the centralized tool in the e-CRF at baseline visit, only after confirming that the participant fulfills all the inclusion/exclusion criteria. Investigator will have to confirm the key eligibility criteria checklist embedded in the system to access to randomization tool in the e-CRF. A statistician from Dijon Bourgogne University hospital, independent of the research, will edit the randomization list, prior to the start of the trial. Breaking of blinding can be requested by the

2 3	24.0	
4 5	218	investigator for occurrence of serious adverse events requiring knowledge of the experimental
5 6 7	219	product to determine the therapeutic course to be taken, by the unblinding function in the
8 9	220	randomization tool in the e-CRF.
10 11 12	221	
13 14 15	222	Objectives
16 17	223	Primary objective
18 19 20	224	The primary objective is to demonstrate the efficacy on adaptive behavior after 24 months of
21 22 23	225	alpelisib treatment.
24 25 26	226	Secondary objectives
27 28	227	To assess: (1) the efficacy of alpelisib vs placebo on adaptive behavior based on the
29 30 31	228	comparison of the proportion of participants with response at 6 months in each group, (2) the
32 33 34	229	impact of alpelisib treatment on cerebral and spinal cord vascularization and volume, (3) the
35 36	230	safety of alpelisib treatment.
37 38 39	231	
40 41 42	232	Exploratory objectives
43 44	233	To evaluate the effects of alpelisib on: (1) adaptive behavior at 6 months, (2) quality of life and
45 46 47	234	clinical global impression, (3) neuropsychological parameters, (4) epilepsy, (5) overgrowth and
48 49	235	skin lesions when appropriate, (6) hypotonia, and (7) to quantify alpelisib passage throughout
50 51 52	236	the blood-brain barrier and its relationship with systemic exposure of alpelisib.
53 54	237	
55 56 57	238	Study Endpoints
58 59 60	239	Primary outcome

BMJ Open

According to the publication by Chatham et al. (18), clinically meaningful improvement will be defined as a gain of at least 4 points in the Vineland II Adaptive Behavior Scale (VABS-II) at 24 months of treatment compared to baseline. The VABS-II is the most widely used scale to assess day-to-day adaptive skills, from birth to adulthood (19, 20). It consists of a form which will be filled during an interview with an adult who is familiar with the daily living activities of the patients (usually a parent). The VABS-II is organized within a three-domain structure: communication, daily living skills, and socialization. In addition, VABS-II has a motor skills domain for children younger than 6 years of age, and an optional maladaptive behavior index (19, 20). The domain (communication, daily living skills, and socialization) standard scores have a mean of 100 and a standard deviation of 15. Adaptive levels can also be determined. A global standard score can also be computed (the Adaptive Behavior Composite standard score) and also has a mean of 100 and a standard deviation of 15.

252 Secondary outcomes

253 For the secondary objectives, the corresponding outcomes will include:

- (1) The response (yes/no) defined as an improvement of at least 4 points in the VABS-II at
 - 6 months of treatment in the alpelisib group compared to the placebo group.
- (2) The changes in brain volume, vascularization, structural connectivity, assessed by MRI,
 from baseline to end of treatment period.
- 258 (3) The number, type and severity of adverse events.

Exploratory outcomes

261 Exploratory endpoints will assess the following:

Page 15 of 35

1

BMJ Open

2		
3 4 5	262	(1) Improvement of at least 4 points in the VABS-II at 12, and 18 months of treatment,
6 7	263	compared to baseline.
8 9	264	(2) Evolution of quality-of-life questionnaires, scores at visual analogue scale, and
10 11	265	evolution of Clinical Global Impression of severity and Global improvement scores at
12 13 14	266	6, 12, 18, 24 months of treatment, compared to baseline.
15 16	267	(3) Changes in neuropsychological scales, adapted to age, at 12 and 24 months of
17 18	268	treatment compared to baseline for attention, cognition, visuo-spatial disorders, fine
19 20 21	269	motor skills, speech, reasoning and cognitive inhibition abilities, and at 24 months of
22 23	270	treatment compared to baseline for IQ scale.
24 25 26	271	(4) Description of changes in seizures frequency (weekly diary), and antiepileptic drugs
27 28	272	use at 6, 12, 18 and 24 months of treatment compared to baseline.
29 30 31	273	(5) Changes in overgrowth or skin lesions, classified as follows: increase, no changes or
32 33	274	reduction in overgrowth or skin lesions according to clinical measures and evaluation
34 35 36	275	of standardized photographs taken at 6, 12, 18 and 24 months of treatment compared
37 38	276	to baseline.
39 40 41	277	(6) Changes in MFM (Motor Function Measure) scores at 6, 12, 18 and 24 months of
42 43	278	treatment compared to baseline.
44 45	279	(7) Level of alpelisib (ng/mL) in cerebrospinal fluid (CSF) and in blood at between 6 or 24
40 47 48	280	months of treatment, and correlation estimate (rho) between CSF and blood levels of
49 50	281	alpelisib.
51 52 53	282	The versions of each scale or questionnaire according to age are detailed in figure 2.
54 55 56 57 58 59	283	Sample size calculation:
60		

BMJ Open

The assumptions are as follows: 1) when following untreated MCAP patients 6.0% at best may have experienced the 4 points improvement, 2) the minimal requirement for the treatment to be considered clinically relevant by regulatory bodies is at least one third of treated patients (33%) experiencing the 4 points improvement. With alpha = 0.05, 1-beta = 0.90 and a bilateral test, 16 patients are needed to prove statistical difference between the theoretical and observed proportion. We are thus planning to enroll and analyze 20 patients to take account of possible loss of follow-up or withdrawal of consent. The approach for sample size calculation is also pragmatic, based on known and estimated cohort. A cohort of about 60 patients with MCAP and PIK3CA pathogenic variant is available, two thirds of them having ID or learning disability that could justify being enrolled in a clinical trial. If a patient is withdrawn from the study before treatment initiation, he will be replaced, to be able to conduct the comparison between alpelisib and placebo groups with 10 patients in each group.

297 PATIENT AND PUBLIC INVOLVEMENT

The feasibility of recruitment is assured by the participation of experts in the clinical and molecular aspects of PROS, including the French reference center for mosaic disorders, the RHU COSY (21), and the French patient's association for MCAP (M-CM France).

302 DATA MANAGEMENT AND DATA ANALYSES

303 Data collection, monitoring and management

304 Clinical, biological and radiological data, will be entered directly into a dedicated e-CRF 305 (electronic Case Report Form) on the CleanWEB platform by the investigators, helped by 306 Clinical Research Associate (CRA). The patient diary is paper-based and will be reviewed by

BMJ Open

the investigator to capture the safety events that will be entered in the e-CRF. Each patient is identified by a unique code including: the number of the recruiting center, the inclusion rank, the initials of the patient (first letter of surname and first name). Automatic gueries due to missing and incoherent data after data entry can be immediately generated by the CleanWEB software. Requests for corrections may also be generated by the methodological support unit of CHU Dijon and sent to the local and/or the evaluation center. The corrections will be made directly in the e-CRF by the investigators, assisted by the CRAs. Histories of changes are systematically recorded. Additionally, a CRA will perform an on-site exhaustive data monitoring for all patients. A data management plan, specific to the study, was prepared before initiating the study in the participating centers.

318 Statistical Analyses

319 Descriptive analysis

Descriptive analysis with presentation of the baseline characteristics of the cohort, with qualitative variables expressed as number of events with their frequencies (%), with their 2sided exact 95% confidence interval (CI). For quantitative variables, mean (±SD) or median (IQR) values will be calculated.

324 Primary outcome analysis

Fisher's exact test or chi square test will be used to compare the observed proportion of patients reaching the primary endpoint after 24 months of treatment to the theoretical proportion of 6%. A p<0.05 will be considered significant.

328 Secondary analyses

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

> The same approach will be used to compare the proportion of responders at M6 between alpelisib and placebo groups. Comparison of brain volumes (affected and unaffected zones) at after 24 months of treatment versus baseline will be performed using a paired-t-test or Wilcoxon rank test according to the distribution priorly assessed by a Shapiro-Wilk test.

> For all safety analyses, data recorded during monitoring for adverse events (AE), either clinical or biological, will be collated and the number, type grade of AE, and their relation to treatment, will be described and the frequencies of AEs recorded as percentages and 95% CI. Results will be presented for the overall 24-month-period of treatment, and also specifically for the double-blind period, to compare safety between alpelisib and placebo. The CTCAE (v5.0) classification will be used to grade the events.

340 Exploratory analyses

Comparison of the mean scores of neuropsychological scale scores obtained at baseline and M24 will be performed using a paired-t-test or Wilcoxon rank test. To test the reliability of the change, the Reliable Change Index (RCI) will be calculated for each psychometric scale (22). For fine reasoning and cognitive inhibition abilities, the raw data (logfiles from Presentation software) will be analyzed automatically using Matlab 7.1. A Reaction Time (RT) and an Error Rate (ER) analysis will be performed using R software (see supplemental material). Change in scores at the MFM test will be assessed by analyzing the slopes of change between scores obtained at 6, 12, 18 and 24 months of treatment vs. baseline for each patient, and expressed as an annual rate using the unweighted least-square estimate. Comparison of mean scores will then be performed using a paired-t-test or Wilcoxon rank test.

Finally, the correlation between CSF level and blood level of alpelisib will be estimated by
 color calculating the factor rho of Spearman's correlation.

1		
2	252	
4	333	
5 6 7	354	Statistical Software
8 9	355	Analysis will be performed using SAS software (version 9.4). Statisticians will be blinded to the
10 11 12	356	study.
13 14	357	
14 15 16	358	METHODS: MONITORING
17 18 19	359	Harms: Steering data and safety monitoring committees
20 21 22	360	The coordinating centre at University Hospital Dijon-Bourgogne, Clinical Investigation Centre
23 24 25	361	(CIC INSERM 1432), is assigned the responsibility of all study aspects: ethical, regulatory, study
26 27	362	coordination, data management and publication strategy.
28 29 30	363	The steering committee is composed by the coordinating investigator, a methodologist, a
31 32	364	pharmacovigilance officer, a pharmacist, a sponsor representative, and the project manager.
33 34 35	365	This committee meets on a weekly basis to assess study progress and solve potential issues.
36 37	366	An independent data safety monitoring board (DSMB) is monitoring the patients' safety during
38 39 40	367	the study and gives recommendations to the steering committee. It is composed of a
40 41 42	368	pharmacologist or pharmacovigilant officer, a metholologist, a neuropediatrician, and a
43 44 45	369	geneticist. The DSMB met when the first 4 included patients (25% of the initially anticipated
46 47	370	number of patients) had completed 1 month of treatment, and will meet again at 50% and
48 49	371	75% of the inclusions. Treatment initiations will be halted at each threshold and will resume
50 51 52	372	after review of the safety data by the DSMB.
53 54	373	
55 56 57 58 59 60	374	ETHICS AND DISSEMINATION

BMJ Open

Authorization was obtained from the French National Drug Safety Agency on 28/07/2022 and from the Ethics Committee (CPP Sud-Ouest et Outre-Mer I) on 22/09/2022 (reference number: 2022-500197-34-01). The protocol was registered with ClinicalTrials.gov under the identifier NCT05577754 in 13/10/2022. Current version of protocol is V3 (25/05/2023). The first patient was included in November 2022 and the study is expected to be completed by 2026.

Results will be presented at scientific meetings and published in international peer-reviewed journals.

DISCUSSION

At present, there is no licensed or unlicensed drug with a proven benefit for patients with MCAP syndrome, although alpelisib FDA's approval for patients with PROS, based on collection of real-world evidence from compassionate use, makes it possible to treat patients with MCAP syndrome. As such, there is a clear unmet medical need. The understanding of the pathophysiology of the PROS and MCAP syndromes, a *PIK3CA* gain-of-function variant, and the development of specific PI3K3 inhibitors in cancer, where the same variants are found, has raised great hopes of eventually providing an effective treatment.

Whereas Novartis Pharmaceutical's sponsored EPIK-P2 is running for patients with PROS, no such study was planned for patients with MCAP syndrome. Even if the data are sparse, Venot et al. reported that the two patients with MCAP syndrome among the 19 patients with PROS syndrome, exhibited improvement in cognitive function, behavior, and cerebral perfusion (15). We therefore hypothesized that alpelisib treatment could be useful for these patients and designed a dedicated trail.

Page 21 of 35

BMJ Open

the co
ublish
fepile
n eva
perien
nal or
g an im
attery
e leve
nents.
future
aradig
impro
les (2
ain vol
at the
of the
otoco
tation
is only

The judgement criteria for the SESAM study were based on llection of complete clinical and radiological data from 33 French patients, which we p ed in 2021 (10). It was this cohort that led us, for example, not to adopt the evolution of ptic seizures as the primary endpoint, as only 10% to 15% of patients suffer from them.

We chose VABS as the primary endpoint, as it has bee luated in clinical trials on neurodevelopmental disorders, to assess the changes exp ced by patients/families in their daily lives (18). Nevertheless, in the absence of nation international consensus on the scales to be used in clinical trials aimed at demonstrating provement in patients with neurocognitive disorders, we have chosen to use a ba of scales, all addressing complementary domains, appropriate to the age, cognitive el, ability of the patients to concentrate, and the time constraints between two assessm We believe that the results of this trial will provide useful information for clinical trials targeting neurodevelopmental pathologies. We added a simplified p m matrix stimuli especially designed by the expert team to try to identify fine points of vement in clinical trials that would be difficult to demonstrate with conventional sca 3). Although we have no certainty about the possibility of achieving a reduction in brack lume, we felt it is important to assess this. Therefore, volumetric MRI will be performed beginning of the study and at the end of the treatment. Given the poor knowledge prevalence of spinal cord abnormalities in MCAP, spinal cord MRI was added to the pr I. Assessing quality of life as well as the effect of alpelisib on other non-brain manifest s of the disease were also planned.

The passage of alpelisib through the blood-brain barrier has been hypothesized, based on the observation of a reduction in the size of brain metastases in women with breast cancer or an improvement in epileptic seizures. It is therefore necessary to assess and quantify the

BMJ Open

passage of alpelisib into the cerebrospinal fluid (CSF), in relation with the plasmatic dosage. This will help to establish a correlation between the plasma concentration and that of the CSF, possibly allowing therapeutic monitoring on the basis of plasma concentrations alone (24). The SESAM trial also benefits from the accumulated experience of our previous trials, one with mTOR inhibitor sirolimus, and the other with taselisib, another PI3K α -specific inhibitor (25, 26). In particular, conducting this trial as part of a well-established network with investigators from local centres, enabling some of the follow-up visits to be carried out close to patients' homes, improves acceptability and ensures that the trial runs smoothly. In addition, by using this two-period design which allows all patients to be treated, we aim to demonstrate that a rigorous methodology can be applied in clinical trials in rare diseases, with high quality standards while preserving the acceptability of the trial's burden for the patient. Based on our preliminary data in CLOVES, we will enhance knowledge relating to the efficacy and side-effect profile associated with long-term treatment with PI3K pathway inhibition, and determine the effectiveness of treatment across an expanded number of PROS. Considering the pathological overlap deriving from the common feature of *PIK3CA* upregulation, our work may also inform future transversal therapeutic strategies in the context of a larger group of diseases. DATASHARING All requests for the study's data will be considered by the SESAM trial steering committee. **TRIAL STATUS** Recruitment is ongoing (16 patients included as of 31/12/2023).

	Protected by o
	Erasmushogeschool . opyright, including for uses related to text and data .
	nining, AI training, and similar technologies.

2		
3	448	REFERENCES
4		
5	449	1. Lindhurst MI, Parker VF, Payne F, Sann JC, Rudge S, Harris I, et al. Mosaic overgrowth with
6 7	450	fibroadinose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet
/ Q	451	
0	452	2012,44(0).520 55.
10	452	2 Pivière IP Mirzaa GM O'Peak PL Peddaqui M Alcantara D. Conway PL et al. De nove
11	455	2. Revenue of the second participation of the second of the second participation of th
12	454 455	magalancanhalu sundramas. Nat Canat. 2012;44(8):024.40
13	455	megalencephaly synuromes. Nat Genet. 2012;44(8):934-40.
14	450	2 Kursk KC Luke M Auturk UNA Alementi AL Fishmen CL Grencer CA et al Comptie measie
15	457	3. Kurek KC, Luks VL, Ayturk Olvi, Alomari Al, Fishman SJ, Spencer SA, et al. Somatic mosaic
16	458	activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 2012;90(6):1108-15.
17	459	
18	460	4. Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, et al. Somatic gain-of-function
19	461	mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet. 2013;22(3):444-51.
20	462	
21	463	5. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene.
22	464	2008;27(41):5486-96.
24	465	
25	466	6. Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T, et al. Molecular diagnosis
26	467	of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic
27	468	testing. Genet Med. 2017;19(9):989-97.
28	469	
29	470	7. Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, et al. Clinical
30	471	delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A.
31 22	472	2014;164a(7):1713-33.
32 33	473	
34	474	8. Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, et al. PIK3CA-
35	475	related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis,
36	476	and evaluation. Am J Med Genet A. 2015;167a(2):287-95.
37	477	
38	478	9. Mirzaa GM, Rivière JB, Dobyns WB. Megalencephaly syndromes and activating mutations in
39	479	the PI3K-AKT pathway: MPPH and MCAP. Am J Med Genet C Semin Med Genet. 2013;163c(2):122-30.
40	480	
41	481	10. Garde A, Guibaud L, Goldenberg A, Petit F, Dard R, Roume J, et al. Clinical and neuroimaging
42 42	482	findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future
45 44	483	clinical trials. Clin Genet. 2021;99(5):650-61.
45	484	
46	485	11. Haute Autorité de Santé Procotole; National de Diagnostic et de Soins for MCAP [Available
47	486	from: https://www.has-sante.fr/upload/docs/application/pdf/2021-10/pnds-mcap_sept_2021.pdf.
48	487	
49	488	12. Douzgou S. Rawson M. Baselga E. Danielpour M. Faivre L. Kashanian A. et al. A standard of
50	489	care for individuals with PIK3CA-related disorders: An international expert consensus statement. Clin
51	490	Genet. 2022:101(1):32-47.
52	491	
53 54	492	13. Arafeh R. Samuels Y. PIK3CA in cancer: The past 30 years. Semin Cancer Biol. 2019:59:36-49
54 55	493	
56	494	14. Andre F. Ciruelos E. Rubovszky G. Campone M. Loibl S. Rugo HS. et al. Alpelisib for PIK3CA-
57	495	Mutated, Hormone Receptor-Positive Advanced Breast Cancer, N Engl J Med. 2019;380(20):1929-40
58	496	
59		
60		

1		
2	407	
5 4	497	15. Venot Q, Blanc I, Rabia SH, Berteloot L, Ladraa S, Duong JP, et al. Targeted therapy in
5	498	patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540-6.
6	499	
7	500	16. Food and Drug Administration - FDA approves alpelisib for PIK3CA-related overgrowth
8	501	spectrum 2022 [updated 04/06/2022. Available from: <u>https://www.fda.gov/drugs/resources-</u>
9	502	information-approved-drugs/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum.
10	503	
11	504	17. Morin G, Degrugillier-Chopinet C, Vincent M, Fraissenon A, Aubert H, Chapelle C, et al.
12	505	I reatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. J Exp Med.
14	506	2022;219(3).
15	507	
16	508	18. Chatham CH, Taylor KI, Charman T, Liogier D'ardhuy X, Eule E, Fedele A, et al. Adaptive
17	509	behavior in autism: Minimal clinically important differences on the Vineland-II. Autism Res.
18	510	2018;11(2):270-83.
19	511	
20	512	19. Sparrow SS, Balla, D. A., & Cicchetti, D. V Vineland adaptive behavior scales: Interview
21	513	edition, survey form manual. Circle Pines, MN: American Guidance Service. 1984.
22	514	
23	515	20. Sparrow SSC, D.V.; Saulnier, C.A. Vineland-3: Vineland Adaptive Behavior Scales. 3rd ed.
24	516	Pearson Assessments; Minneapolis, MN, USA. 2016.
25	517	
20	518	21. Recherche Hospitalo Universitaire (RHU) - Cure Overgrowth Syndromes (COSY) [Available
28	519	from: <u>https://rhu-cosy.com/</u> .
29	520	
30	521	22. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful
31	522	change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12-9.
32	523	
33	524	23. Curie A, Brun A, Cheylus A, Reboul A, Nazir T, Bussy G, et al. A Novel Analog Reasoning
34 25	525	Paradigm: New Insights in Intellectually Disabled Patients. PLoS One. 2016;11(2):e0149717.
36	526	
37	527	24. Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM. Response of Brain Metastases
38	528	From PIK3CA-Mutant Breast Cancer to Alpelisib. JCO Precis Oncol. 2020;4.
39	529	
40	530	25. Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, et al. Safety and
41	531	efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet Med.
42	532	2019;21(5):1189-98.
43	533	
44 45	534	26. Luu M, Vabres P, Devilliers H, Loffroy R, Phan A, Martin L, et al. Safety and efficacy of low-
45 16	535	dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunav syndrome (KTS):
40 47	536	the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study. Genet Med.
48	537	2021;23(12):2433-42.
49	538	
50	230	
51	E 2 0	
52	222	
53		
54	540	
55 56		
57	541	
58		
59	542	
60		

3 4 5	543	FULL LIST OF CO-INVESTIGATORS OF THE SESAM STUDY GROUP
6 7	544	Dr Benedicte Demeer (CHU Amiens) ; Dr Estelle Colin (CHU Angers) ; Dr Elise Boucher-
8 9 10	545	Brischoux (CHU Besançon) ; Adélaïde Brosseau-Beauvir (CHU Brest) ; Dr Christine Francannet
10 11 12	546	(CHU Clermont Ferrand) ; Dr Florian Cherik (CHU Clermont Ferrand) ; Pr Jean-Marc Treluyer
13 14 15	547	(CHU Cochin) ; Pr Florence Petit (CHU Lille) ; Pr Alice Phan (CHU Lyon) ; Dr Michaela SEMERARO
16 17	548	(Necker AP-HP); Dr Marion Nys (Necker AP-HP); Dr Charles Joris Roux (Necker APHP); Dr
18 19 20	549	Philippe Khau Van Kien (CHU Nimes) ; Dr Alinoë Lavillaureix (CHU Rennes) ; Pr Isabelle Maruani
20 21 22	550	(CHRU Tours) ;
23 24	551	
25 26 27 28	552	AUTHORS' CONTRIBUTIONS :
29 30	553	LF and VB initiated this study. LF, ML, MB designed the study. ML has written this manuscript.
31 32 33	554	LF, MB, AM, MC (sponsor), and Novartis Pharmaceuticals (sponsor) reviewed the manuscript.
33 34 35	555	All authors read and approved the final manuscript.
36 37 38	556	
39 40	557	FUNDING
41 42 42	558	This study was co-funded by Novartis Pharmaceutical and the University Hospital of Dijon
45 44 45	559	Bourgogne.
46 47	560	
48 49 50	561	CONFLICTS OF INTEREST
51 52	562	A patent application ("BYL719 (alpelisib) for use in the treatment of PIK3CA-related
53 54 55	563	overgrowth spectrum" #WO2017140828A1) has been filed by INSERM (Institut National de la
56 57	564	Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS),
58 59 60	565	Université Paris Cité, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719

BMJ Open

BMJ Open

2	
2	
4	
5	ı
6 7	•
7 8	ı
9	•
10	ı
11	•
12	ı
14	
15	ı
16	
17 18	I
19	
20	I
21	
22 23	I
23 24	
25	I
26	-
27 29	ļ
20 29	
30	ļ
31	
32	ļ
33 34	
35	ļ
36	
37	ļ
38	
40	
41	
42	ļ
43	
44 45	
46	
47	
48	
49 50	
51	
52	
53	
54 55	
55 56	
57	
58	
59	
60	

566	(alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS/CLOVES
567	syndrome). Dr. Canaud is the inventor. This patent is licensed to Novartis Pharmaceutical.
568	
569	ML has received consulting fees from Novartis Pharmaceutical. GC receives or has received
570	consulting fees from Novartis Pharmaceutical, Fresenius Medical Care, Vaderis, Alkermes,
571	IPSEN and BridgeBio.
572	
573	
574	LEGENDS
575	Figure 1. Study design of the SESAM trial
576	
577	Figure 2. Neuropsychological tests used in the SESAM trials. Tests were selected according to
578	the conclusions of a working group from the DéfiScience Network (www.defiscience.fr), which
579	assessed all the neuropsychological tests available for each domain and adapted to ID
580	patients. The 20-item Motor Function Measure (MFM20) will be administered for children <7
581	yo, and the MFM32 for children ≥7yo.
582	

BMJ Open: first published as 10.1136/bmjopen-2024-084614 on 20 December 2024. Downloaded from http://bmjopen.bmj.com/ on May 20, 2025 at Department GEZ-LTA

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Ŷ



Group A Double-blind period + 6 months Open label period - 24 months ALPELISIB PLACEBO V134 M15 M6 +2W V15^L M21 V8^F M6 V10 V11 V12⁰ M12 V140 M18 V16 M24 M7 M9 M27 V1^L inclusion M-3/D-1 V2^d +1W V3^F V4 V5¹ M1 V6¹ МЗ **V-FUp** (30 days after EOT) V10^L M15 Baseli W1 W2 V8L M9 V9^C M12 V11^C M18 V12^L V13 D0 to D2/D3 M24 M21 ALPELISIB Double-blind period - 6 months Open label period - 18 months Group B L : visit at local site ; C : visit at coordinating site ; P: Phone visit by coordinating site ; V-FUp : Follow-up visit 30 days after end of treatment Safety call (monthly) + Quarterly Dispensation Study design of the SESAM trial 254x190mm (96 x 96 DPI)

59 60

1									
1									
2									
4									
5									
6	////// muserie to								
7	Patient	Age 2 yo	7 уо 12 у	yo 1	7 уо	22 уо	27 уо	32 yo 37	уо
8	VABS II								
9	CGI-S /	CGI-I			İ.				
10	Intellectua	I Quotient							
11	Wechsler	scale	V 7 yo 7 months		16.00				
12	Mild to	6 yo o moderate ID	WISC-V	16 yo	11 months	W	AIS-IV		79 yo 11 month
13	WNV	4 yo	WNV 17 yo 11 months						
14 15	With no J	language skill	8γο	WNV		21 yo 11 months			
15	Lézine sc	ale months							
10	Cognitive f	scale 5 ve			16 ye				
17	CMS	S yo			11 months 16 yo 11 months				
19	MEM IV			16 yo					
20	Quality of PedsQL 4	Life				25 vp			
21	San Mart	in			18 yo				
22	Motor Fur	nction Measure							
23	MFM								
24									
25	Neuropsychol	ogical tests us	ed in the SES	AM trials.	Tests we	re selected	according	g to the con	clusions of a
26	WORKIR	ng group from nical tests avai	the Defiscient	domain a	rk (WWW.C	ed to ID n	.Tr), WNICN atients Th	assessed a	III the Motor Function
27	Measure	e (MFM20) will	be administe	red for ch	ildren <7	yo, and the	ne MFM32	for children	≥ 7 yo.
28		. ,							
29 30			338	x190mm	(300 x 30	00 DPI)			
31									
32									
33									
34									
35									
36									
37									
38									
39									
40									
41 40									
42									
44									
45									
46									
47									
48									
49									
50									
51									
52									
53									
54									
55									
56									
5/									
50 50									
60		For peer revi	ew only - http	://bmjope	n.bmj.con	n/site/abo	ut/guidelin	es.xhtml	
		-			-				

SUPPLEMENTAL MATERIAL

Annex 1. Complete list of inclusion and exclusion criteria

- 1. Signed informed consent and assent (when applicable) from the patient, parent, or guardian must be obtained prior to any study related screening procedures are performed.
- 2. Male or female patients age ≥ 2 years and ≤ 40 years at the time of informed consent
- 3. Patients with diagnosis of MCAP* with neurodevelopmental disorder presentation (from specific learning disorder to severe intellectual disability) The most recent set of diagnostic criteria for MCAP includes five core features: progressive megalencephaly (criterion 1), developmental vascular disorders (criterion 2), distal limb anomalies (criterion 3), cortical brain malformations (criterion 4), connective tissue dysplasia (criterion 5) plus supportive features. MCAP syndrome is diagnosed in the presence of criterion 1 plus either criterion 2 or criterion 3 (Mirzaa et al., 2013). The absence of criterion 2 and 3 can be accepted in constitutional variant.
- 4. Documented evidence of a somatic or constitutional mutation(s) in the PIK3CA gene performed in local laboratories using a Deoxyribonucleic acid (DNA) based validated test at the time of informed consent.
- 5. Adequate bone marrow and organ function (assessed during the screening visit):
 - a. Absolute neutrophil count $\ge 1.5 \times 109/L$
 - b. Platelets $\geq 100 \times 109/L$
 - c. Hemoglobin ≥ 9.0 g/dL (transfusions are allowed)
 - d. Calcium (corrected for serum albumin) and magnesium within normal limits or ≤Grade 1 according to NCI-CTCAE version 5.0 if judged clinically not significant by the investigator
 - e. Potassium within normal limits.
 - f. INR ≤1.5
 - g. Creatinine Clearance ≥ 30 mL/min using Modification of Diet in Renal Disease (MDRD) (≥18 years old) or creatinine-based Bedside Schwartz (<18 years old) Glomerular filtration rate (GFR) equation
 - h. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \leq 2.5 × ULN.
 - i. Total bilirubin< ULN except for patients with Gilbert's syndrome who may only be
 - j. Fasting plasma glucose (FPG) ≤ 140 mg/dL (7.7 mmol/L) and Glycosylated hemoglobin (HbA1c) ≤ 6.5% (both criteria have to be met)
 - k. Fasting Serum amylase $\leq 2 \times ULN$
 - I. Fasting Serum lipase ≤ ULN
- 6. Able to swallow study drug according to age: tablets, or as drinkable suspension, or granules (under development)
- 7. For women of child-bearing potential only: negative pregnancy test at screening visit
- 8. Male patients with sexual partners who are pregnant, possibly pregnant or who could become pregnant should use condoms during sexual intercourse for the duration of the study and for one week following discontinuation of alpelisib.
- 9. For exploratory study only: signed informed optional consent for lumbar puncture

EXCLUSION CRITERIA

Participants meeting any of the following criteria are not eligible for inclusion in this study:

- 1. Patient previously treated with alpelisib
- 2. Known impairment of GI function due to concomitant disease that may significantly alter the absorption of the study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) at time of informed consent.
- 3. Participant with uncontrolled diabetes mellitus (Type I or II) at time of informed consent.
- 4. History of hypersensitivity to any drugs or metabolites of PI3K inhibitor or any of the excipients of alpelisib at time of informed consent.
- 5. Participant with other concurrent severe and/or uncontrolled medical conditions that would, in the treating Physician's judgment, contraindicate administration of alpelisib (e.g., active and/or uncontrolled severe infection, chronic active hepatitis, hepatic impairment Child Pugh score C, immuno-compromised, etc.) at time of informed consent.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18 19

20

21

22

23

24

25

26

27

28

29 30

31

32

33

34

35

36

37

38

39 40

41

42

43

44

45

46

47

48

49

50

51

52

53 54

55

56

57

58

59 60

6. Female participants of childbearing potential and male participants who do not agree at time of informed consent to abstinence or, if sexually active, unwilling to use a condom and/or a highly effective method of contraception for the duration of the study and for one week following discontinuation of alpelisib. Highly effective contraception methods is one of the following: Total abstinence: when this is in line with the preferred and usual lifestyle of the subject. a. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception b. Female sterilization: have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before taking alpelisib. In case of oophorectomy alone, only when the reproductive status of the female has been confirmed by follow-up hormone level assessment Male sterilization at least 6 months prior to screening. The vasectomized male partner should c. be the sole partner for that study participant d. Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF. 7. Treatment by any mTOR or PI3K-AKT signaling pathway inhibitor within 1 monthbefore inclusion 8. History of prior and or ongoing malignancy (within 5 years before informed consent except radically treated Carcinoma in situ of radically treated basal-cell carcinoma of skin or thyroid gland well differentiated microcarcinoma or Stage 1 Wilms' tumor of a histology other than anaplastic), or ongoing investigations or treatment for malignancy at time of informed consent. 9. Treatment with strong inducers of CYP3A4 and inhibitors of Breast Cancer Resistance Protein (BCRP) that cannot be stopped at least the week prior to the screening 10. Debulking or other major surgery performed within 3 months at time of informed consent 11. Known history of Steven Johnson's syndrome, erythema multiform or toxic epidermal necrolysis at time of informed consent. 12. For participants \geq 6 years of age: Participants with documented pneumonitis or interstitial lung disease at the time of informed consent and with impaired lung function (e.g., FEV1 (Forced expiratory volume) or DLCO (Diffusing Capacity of the Lung for Carbon Monoxide) ≤ 70% of predicted) that is not related to PROS. 13. For participants between 2 to 5 years of age: Participants with documented or suspicious pneumonitis or interstitial lung disease based on MRI images at time of informed consent. 14. History of acute pancreatitis within 1 year before informed consent or past medical history of chronic pancreatitis at time of informed consent. 15. Clinically significant heart disease at time of informed consent, including: a. History of documented congestive heart failure (New York Heart Association functional classification III-IV) b. Clinically significant uncontrolled cardiac arrhythmias c. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome d. Corrected QT (QTcF) at screening: >470 ms for ≥18 years old / >450 ms for <18 years old Creatinine clearance < 70ml/min/1.73 m² e. 16. Patient currently, or in the 3 months before inclusion, enrolled in another interventional trial. 17. Person not affiliated to a national health insurance scheme 18. Patient, parents or legal authorized representative incapable of expressing consent 19. Inability to attend all trial visits 20. For the optional lumbar puncture only : known intracranial hypertension, active infection at puncture site, known coagulation disorders, Platelets < 50 × 10₉/L

BMJ Open

Annex 2a. Assessment Schedule for Group A : patients allocated to placebo during double-blind period

44 45 46

nnex 2a. Assessment Schedu	le for Gr	oup A : µ	patients all	ocated	to plac	ebo di	BM uring	lJ Open double-bl	ind per	iod			mjopen-20 vy copyrigh						Pag	je 3				
Pariod		Sarooping		ouble-blind	I period · Pl	ACEBO tr	eatment					0		ariod: AL	PELISIB troat	nent								
Study duration		max 3 m	D0	W1	w2	M 1	M3	M6	M 6+1W	M 6+2W	M7	М9		M 15	M 18	M21	M 24	M 27	M 30					
treatment duration		maxom	50		112	141 1	IN S	WO	1w	2w	1m	3 m	<u><u><u></u><u></u><u></u><u>6</u><u>m</u><u></u><u></u><u>6</u><u>m</u><u></u><u>6</u><u>m</u></u></u>	NI IS	12 m	IVI Z I	18 m	10127	24 m	+				
	Visit 0	Visit 1	Visit 2	T	I			Visit 7					ū√isit 🕅			1		1	Visit 18	V				
Visit Name				Visit 3	Visit 4	Visit 5	Visit 6	Interim	Visit 8	Visit 9	Visit 10	Visit 11		Visit 13	Visit 14	Visit 15	Visit 16	Visit 17	End of	_				
	Information	Inclusion	Baseline					evaluation											treatment	f				
								Baseline						_					(EOT)	<u> </u>				
Week	<w-12< td=""><td>W-12 to D-1</td><td>D0 to D2 or D3</td><td>W1</td><td>W2</td><td>W4</td><td>W12</td><td>W24</td><td>W25</td><td>W27</td><td>W28</td><td>W36</td><td>c ^{W5}20</td><td></td><td>W72</td><td></td><td>W104</td><td></td><td></td><td>4</td></w-12<>	W-12 to D-1	D0 to D2 or D3	W1	W2	W4	W12	W24	W25	W27	W28	W36	c ^{W5} 20		W72		W104			4				
Site	Assessment	Local	Assessment	Phone call	Local	Local	Local	Assessment	Phone call	Local	Local	Local	Ansessmen	t Local	Assessment	Local	Assessment	Local	Assessmen	nt				
													ö ö	± 14		± 14		± 14		+				
Window s allow ed				±1 days	±2 days	±7 days	±7 days	±7 days	±1 days	± 2 days	±7 days	±7 days	11:7 da@os	days	± 14 days	days	± 14 days	days	± 14 days					
nformed Consent	Information	•											hb Iat											
nclusion/exclusion criteria	•	•											le as er							T				
)emography		•											<u>438</u>							+				
													<u>۲. کر ک</u>							+				
		•											<u>4 č š l</u>											
ion drug therapies/surgical /medical		•							Continuous	up to 30 day	s after the	last dose	စန်းမြို့မှ ကြား	tment										
rocedures									<u> </u>		<i>c</i> , , ,													
Concomitant medications		•							Continuous	up to 30 day	s after the	last dose		tment		1	1	1	1					
Physical examination		•	•		•	•	•	•		•	•	•	<u>0</u> 7 0	•	•	٠	٠	•	•	_				
/ital Signs		•	•		•	•	•	•		•	•	•	at on a	•	•	•	•	•	٠					
ísual Analogue Scale			•					•					u i eq				•		•					
ectrocardiogram (EKG)		•	•		•	•		•		•	•				•		٠		•	Т				
igital Photography of affected areas			•					•					<u>≓</u> • •		•		•		•	-				
Again Protography of directed dread			-										<u></u>						•	+				
			-					-						-					-	+				
			•										- -	-					•	+				
pinal cord MRI •			•						•										•	+				
llood sample		•	•	•	•	•	•	•	•	•	•	•	5. • 9	•	•	•	•	•	٠	_				
IbA1C		•					•	•				•	5. • 4	•	•		•		•					
lepatitis and HIV		•							2				9, 9,											
Pregnancy test*		•	•			•	٠	•			•	•	ar •h	•	•	•	•	•	•	Т				
)ne optional lumbar puncture + blood													<u>a</u> <u>-</u>							T				
ample for alpelisib dosages	optional								Ť				<u>v</u> . • 3		•		•		•					
etween 6 to 24months of treatment	consent												3											
			•					•					<u>ه</u>		•		•		•	+				
ADO-II			-					-						-					-	+				
			•										8 2	-						+				
kevised Brunet-Lezine scale ***		ļ	•	ļ									<u> </u>		<u> </u>		ļ		•	╇				
IEPSY-II ***			•										5	_	•	<u> </u>			•	4				
CMS/MEM***			•												•				•					
GI-S and CGI-I			CGI-S					•					20 gi		•		•		•					
ine reasoning and inhibition abilities			•					•					S •N		•		•		•	Т				
oLguestionnaire ***			•					•					•0		•	1	•		•	T				
/FM scale			•					•					<u>_</u> 01	1	•	1	•	1	•	+				
andomisation			-					-					<u> </u>	+	<u> </u>		<u> </u>		<u> </u>	+				
													0	+ -	-	<u> </u>	-	-		+				
tudy Drug Dispensation			•	ļ	ļ		•	•				•	• •	•	•	•	•	•	ļ	╉				
Ionitoring post first administration			 during 30mins 		ļ			 during 30mins 			<u> </u>		Sa		ļ					4				
ducation of guardians on clinical			-					-					1 -	1		1								
igns of alpelisib toxicity/overdos													ne											
Inblinding data								 post evaluation 					ň			1				Ţ				
pilepsiy daily diary			1	-	-			-		daily dia	ry complet	ed by pati	ent O				-		Pag					
/edical diary													<u> </u>											
aily dosing and any AF experienced										daily dia	ry complet	ed by pati	ent N											
																-		-	r					

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 33 of 35

BMJ Open

Annex 2b. Assessment Schedule for Group B : patients allocated to alpelisib during double-blind period

3 of 35						BM.	J Open				y cop				
Annex 2b. Assessment Schedule	e for Grou	ıр B : pa	tients alloca	ited to a	lpelisib	during	double-	blind period	d		yrigh	2			
Period		Screening		Double-blir	nd period : /	ALBELISIB ti	eatment			0	pe n -labe	period: ALPE	LISIB treatn	nent	
Study duration /patient		max 3 m	D0	W1	W2	M 1	M 3	M 6	M 9	M 12	<u>0</u> M 15	M 18	M 21	M 24	-
treatment duration) (i= # 0	1/1-14.4) //- # O	1w	2w	1m	3 m	6 m		12 m	C 15m	18m	21m	24m	_
	VISILU	VISILI	VISIL 2					VISIL 7			li i	1		Find of	_
Visit Name	Information	Inclusion	Baseline	Visit 3	Visit 4	Visit 5	Visit 6	Interim	Visit 8	Visit 9		Visit 11	Visit 12	treatment	t
								evaluation			<u> </u>	1		(EOT)	_
Week	<w-12< td=""><td>W-12 to D-</td><td>D0 to D2 or D3</td><td>W1</td><td>W2</td><td>W4</td><td>W12</td><td>W24</td><td></td><td>W52</td><td></td><td>3</td><td></td><td>W104</td><td></td></w-12<>	W-12 to D-	D0 to D2 or D3	W1	W2	W4	W12	W24		W52		3		W104	
0.14-	Assessment	Lesel	Assessment	Deepe cell	Least	Lesel	Leeel	Assessment	Leeel	A	<u> </u>	A	Lagal	A	
Site	Assessment	Local	Assessment	Phone call	Local	Local	Local	Assessment	Local	Assessmen	O -Ocar	Assessment	Local	Assessmen	
Windows allowed				± 1 days	±2 days	±7 days	±7 days	±7 days	±7 days	±7 days		± 14 days	± 14 days	± 14 days	,
nformed Consent	Information	•	•												-
											88.				-
	-			-							525	ŧ			-
				-						1	2 2 2 2				-
Viedical and surgical history		•									ڹڲٚۿۣڗ	<u> </u>			_
Non drug therapies/surgical/medical		•					Continuous	up to 30 days afte	r the last do	se of study tre	atroveno				
							Continuous	up to 30 days afte	r the last do	se of study tre	<u> </u>				-
		•					Containadas	up to 50 days arte		se of study fre				-	
		•	•			•	•	•	•	•	202	•	•	•	_
Vital Signs		•	•			•	•	•	•	•	<u> </u>	•	•	•	
Visual Analogue Scale			•			-		•		•		•		•	
Electrocardiogram (EKG)		•	•		•	•		•		•	i c	•		•	
Digital Photography of affected areas			•					•		•	ē -	•		•	_
Measurements of hypertrophic areas			•					•						•	
Brain MRI			•				2				lt t			•	
Spinal cord MRI •			•								ai.			•	
Blood sample		•	•	•	•	•	•	•	•	•	nii	•	•	•	
HbA1C		٠					•		•	•	β	•		•	
Hepatitis and HIV		•									a 6				
Pregnancy test*		•	•			•	•	•		•	2.	•	•	•	-
One optional lumbar puncture + blood										1	S S				-
sample for alpelisib dosages	optional							•		•	lä 🗧	•		•	
between 6 to 24months of treatment	consent														
VABS-II			•					•		•		•		•	-
Nechsler scale and profil** /***			•								l d d			•	-
Revised Brunet-Lézine scale ***	İ	1	•	1	1	1			1		1 -	1	1	•	-
			•							•				•	-
2MS/MEM***			•								<u></u>			-	-
			CGLS					•							-
			00+0					•			lö k				
			•					•		•	· ·			-	-
			•					•		•	ć	•		•	
MFM scale			•					•		•	2	•		•	
Randomisation			•								5	1			
Study Drug Dispensation			•				•	•	•	•	• •	•	•		
Monitoring post first administration			eduring 30 min								<u> </u>				
Education of guardians on clinical													1		
signs of lithium toxicity/overdos			•					•			g				
Jnblinding data								•post evaluation					1		
Epilepsiy daily diary								daily diary cor	npleted by pa	atient	6	,			
Medical diary		1						alaihu -ti	malated by	ationt	- N	i i			-
daily dosing and any AE experienced								dally diary cor	ipleted by p	auent	ŕ	-			
	1	e †	•				-		-					•	-

children: Control of the contro
Annex 3. Computer task for visual analogical reasoning paradigm

Simple Matrices task

The simplified paradigm matrix stimuli especially designed by the expert team consist of four elements (instead of the nine cells in Raven's), with two response choices (instead of the eight in Raven's). Four parameters are involved in matrix creation: color (white, black or grey), form (round, square or triangle), number (one or two), and size (large or small). The number of relations between the items that need to be considered jointly to find the correct answer define the relational complexity of a matrix.

There are three levels of complexity:

- Identical: the three elements of the matrix are the same (Figure 1a);
- "One-relation" (Figure 1b): a very simple reasoning that requires consideration of only one varying parameter;
- "Two-relations" (Figure 1d): variation in two parameters must be integrated to get the correct answer.



All the elements are the same





 1b. One-relation matrix with neutral response (1R_Neu) Form variation should be integrated to get the right answer
 1c. One-relation matrix with "to be inhibited" false response (1R_Inhib)



1e. Two-relations matrix with "to be inhibited" false response (2R_Inhib)

Example of the 5 conditions included in the task (from Curie et al., 2016)

Furthermore, false-responses of two different types exist: a "neutral" response, which is a choice different from the items displayed in the matrix (Figure 1b and 1d) and a "to be inhibited" response, which is identical to one of the matrix items displayed (Figure 1c and 1e). Thus, this task combines 5 different conditions: identical matrices (Id), one-relation matrices with neutral responses (1R_Neu), onerelation matrices with to be inhibited responses (1R_Inhib), two-relations matrices with neutral responses (2R_Neu) and two-relations matrices with to be inhibited responses (2R_Inhib).

Task Description/data acquisition

The participants are asked to identify the missing element that completes a pattern. The stimuli are displayed on a computer screen. Participants are told to find the best answer to fill in the missing "piece". For the patients, immediate visual feedback via a happy or sad emoticon (in case of right or

wrong answer, respectively) is given during the training to make the task easier to understand. The paradigm will consist of four runs. Each matrix is preceded by a fixation cross. The subject then has to select the correct answer by pushing a button. The number of each type of condition will be counterbalanced on each run, producing the same number of right and left answers. For each type of matrix, the type of variable relation (form, color, size, number) will also be counterbalanced. The order of different conditions in the matrix display will be randomized, as is the side of the correct answer. Each run consists of 45 trials in the behavioral task and 15 trials in the eyetracking task. The matrices are generated and displayed using Presentation software (http://www.neurobs.com). A break will be allowed if necessary between two runs.

to peet eview only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

A Phase II double-blind multi-center, placebo-controlled trial, to assess the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP) – the SESAM study protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-084614.R1
Article Type:	Protocol
Date Submitted by the Author:	20-Nov-2024
Complete List of Authors:	Luu, Maxime; Centre Hospitalier Universitaire de Dijon, Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD) Vabres, Pierre; Centre référence MAGEC, Dermatology; St John's Institute of Dermatology, Espitalier, Aurélie; Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Maurer, Agnès; Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Garde, Aurore; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Racine, Caroline; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Racine, Caroline; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Dijon, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD Carpentier, Maud; Centre Hospitalier Universitaire de Dijon, Direction de la Recherche Clinique Rega, Adélaide; Centre Hospitalier Universitaire de Dijon, Département de Radiologie et Imagerie Diagnostique et Thérapeutique Loffroy, Romaric; Centre Hospitalier Universitaire de Dijon, Département de Rádiologie et Imagerie Diagnostique et Thérapeutique Hadouiri, Nawale; Centre Hospitalier Universitaire de Dijon, Département of Médecine Physique et de Réadaptation Boddaert, Nathalie; Hôpital Universitaire Necker-Enfants Malades, INSERM UMR-1163 Institut Imagine; Hôpital Universitaire Necker-Enfants Malades, Département de Radiologie Pédiatrique Curie, Aurore; Hospices Civils de Lyon, Centre de référence Déficience Intel

	Pharmacologie périnatale, pédiatrique et adulte (site HEGP), Recherche Clinique Entrepôts de Données et Pharmacologie, GHU Paris. Université Paris Cité Charligny, Julie; Centre Hospitalier Universitaire Dijon Bourgogne, Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432 Kuentz, Paul; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire de Besancon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI Canaud, Guillaume; Assistance Publique - Hopitaux de Paris, INSERM UMR-1163 Institut Imagine, Hôpital Necker-Enfants Malades; Université Paris Cité, INSERM U1151, Unité de médecine translationnelle et thérapies ciblées, Hôpital Necker-Enfants Malades Bahi-Buisson, Nadia; Assistance Publique - Hopitaux de Paris, Département de Radiologie Pédiatrique, Hôpital Necker-Enfants Malades; Assistance Publique - Hopitaux de Paris, Service de Neurologie Pédiatrique, DMU MICADO, Hôpital Necker Enfants Malades Fleck, Camille; Centre Hospitalier Universitaire Dijon Bourgogne, Direction de la Recherche Clinique Cransac, Amelie; Centre Hospitalier Universitaire Dijon Bourgogne, Département de Pharmacie; Université de Bourgogne, INSERM LNC- UMR1231 Bardou, Marc; Centre Hospitalier Universitaire Dijon Bourgogne, Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD) Faivre, Laurence; Université de Bourgogne, INSERM UMR1231 Génétique des Anomalies du Développement (GAD); Centre Hospitalier Universitaire Dijon Bourgogne, Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD
Primary Subject Heading :	Genetics and genomics
Secondary Subject Heading:	Paediatrics, Pharmacology and therapeutics, Neurology
Keywords:	Developmental neurology & neurodisability < PAEDIATRICS, Clinical trials < THERAPEUTICS, Paediatric clinical genetics & dysmorphology < GENETICS, Neurogenetics < NEUROLOGY
	-

SCHOLARONE[™] Manuscripts

BMJ Open

1	A Phase II double-blind multi-center, placebo-controlled trial, to assess the efficacy and
2	safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary
3	malformation Polymicrogyria syndrome (MCAP) – the SESAM study protocol
4	Maxime Luu ^{1,2} , Pierre Vabres ³ , Aurélie Espitalier ⁴ , Agnès Maurer ⁴ , Aurore Garde ^{2,4} , Caroline
5	Racine ^{2,4} , Maud Carpentier ⁵ , Adélaide Rega ⁶ , Romaric Loffroy ⁶ , Nawale Hadouiri ⁷ , Nathalie
6	Boddaert ^{8,9} , Aurore Curie ¹⁰ , Laurent Guibaud ¹¹ , Mouna Chebbi ¹² , Paul Kuentz ^{2,13} , Julie
7	Charligny ¹ , Guillaume Canaud ^{8,14} , Nadia Bahi-Buisson ^{9, 15} , Camille Fleck ⁵ , Amélie Cransac ^{16,17} ,
8	Marc Bardou ^{1,2} ⁺ and Laurence Faivre ^{2,4} ⁺ for the SESAM study group
9	
10	Author Affiliations
10	Author Anniations
11	¹ Centre d'investigation clinique – module plurithématique (CIC-P) INSERM 1432, Centre
12	Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France
13	² INSERM UMR1231 Génétique des Anomalies du Développement (GAD), Université de
14	Bourgogne, Dijon, Bourgogne, France
15	³ Centre référence MAGEC, Dijon, France.
16	⁴ Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU
17	TRANSLAD, Centre Hospitalier Universitaire de Dijon, Dijon, France
18	⁵ Direction de la Recherche Clinique, Centre Hospitalier Universitaire de Dijon, Dijon,
19	Bourgogne, France
20	⁶ Département de Radiologie et Imagerie Diagnostique et Thérapeutique, Centre Hospitalier
21	Universitaire de Dijon, Dijon, Bourgogne, France
22	⁷ Département of Médecine Physique et de Réadaptation, Centre Hospitalier Universitaire de
23	Dijon, Dijon, Bourgogne, France

BMJ Open

2		
3 4	24	⁸ INSERM UMR-1163 Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
5 6 7	25	⁹ Département de Radiologie Pédiatrique, Hôpital Necker-Enfants Malades, AP-HP, Paris,
8 9	26	France.
10 11 12	27	¹⁰ Centre de référence Déficience Intellectuelle de causes rares, Service de neuropédiatrie,
12 13 14	28	Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.
15 16	29	¹¹ Service d'Imagerie Pédiatrique, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron,
17 18 19	30	France.
20 21	31	¹² Service de Pharmacologie périnatale, pédiatrique et adulte (site HEGP), Recherche Clinique
22 23 24	32	Entrepôts de Données et Pharmacologie, GHU Paris. Université Paris Cité, Assistance Publique
25 26	33	Hôpitaux de Paris (APHP)
27 28 20	34	¹³ Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, CHU Besançon,
30 31	35	Besançon, France
32 33	36	¹⁴ INSERM U1151, Unité de médecine translationnelle et thérapies ciblées, Hôpital Necker-
34 35 36	37	Enfants Malades, Université Paris Cité, AP-HP, Paris, France.
37 38	38	¹⁵ Service de Neurologie Pédiatrique, DMU MICADO, APHP, Hôpital Necker Enfants Malades,
39 40 41	39	75015 Paris, France.
42 43	40	¹⁶ Département de Pharmacie, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne,
44 45 46	41	France
47 48	42	¹⁷ INSERM LNC-UMR1231, Université de Bourgogne, Dijon, France
49 50 51	43	
52 53	44	Corresponding author:
54 55	45	Maxime LUU
50 57 58	46	maxime.luu@chu-dijon.fr;
59 60	47	Tel.: (+ 33 380 295 892)

2	
3	
1	
4	
5	
6	
7	
Q	
0	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
10	
18	
19	
20	
21	
 วว	
22	
23	
24	
25	
26	
20	
27	
28	
29	
30	
21	
21	
32	
33	
34	
35	
36	
50	
37	
38	
39	
40	
10	
41	
42	
43	
44	
45	
40	
40	
47	
48	
49	
50	
50	
51	
52	
53	
54	
56	
22	
56	
57	
58	
50	
59	

60

1

51

48 Name and contact information for the trial sponsor:

49 Maud CARPENTIER

50 maud.carpentier@chu-dijon.fr

for peer teriew only

Abstract:

1 2

3	
4	
5	
6	
7	
/ 0	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
25	
20	
27 20	
20	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40 47	
47 40	
40 40	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

53	Introduction
54	The MCAP syndrome (Megalencephaly Capillary malformation Polymicrogyria) results from
55	mosaic gain-of-function PIK3CA variants. Main clinical features are macrocephaly, somation
56	overgrowth, neurodevelopmental delay, and brain anomalies. Alpelisib (Vijoice®) is a recently
57	FDA-approved PI3K α -specific inhibitor for patients with PIK3CA-related overgrowth spectrum
58	(PROS). During its development, in patients with MCAP subgroup of PROS, there was no
59	specific, standardised evaluation of the effect on neuro-cognitive functioning. Moreover, in
60	remains unknown if the molecule crosses the blood-brain barrier. Our objective is to evaluate
61	the efficacy of a 24-month treatment with alpelisib on adaptive behaviour in patients with
62	MCAP syndrome.
63	Methods and Analysis
64	SESAM is an industry-sponsored two periods multi-centre French academic phase II trial, with

a 6 months double-blind, placebo-controlled period followed by open label period. Primary 65 endpoint is a \geq 4 points improvement in the Vineland II Adaptive Behavior Scale (VABS), 24 66 months after treatment initiation. Secondary objectives are safety, VABS improvement at 6 67 68 months, impact on quality of life, epilepsy and hypotonia. Twenty patients aged 2 to 40 years old, with a MCAP diagnosis and neurodevelopmental disorders of various degrees, will be 69 70 followed monthly in local centres, centrally assessed (clinical, biological, neuropsychological and functional evaluation) at baseline and every 6 months. Patients will be evaluated by 71 volumetric MRI at baseline and at 24 months. An optional lumbar puncture will be performed 72 73 to investigate blood-brain barrier crossing. Inclusions were completed by April 2024, with the end of follow-up in November 2026. 74

BMJ Open

- Given the efficacy of alpelisib in patients with PROS, if the drug crosses the blood-brain barrier,
- we can expect a clinical benefit for patients with neurocognitive disorders.

Ethics and dissemination

- Ethical approval was given by CPP Sud-Ouest et Outre-Mer I (reference: 2022-500197-34-01).
- Findings from this study will be disseminated via publication, reports and conference , ClinicalTrials.gc
- presentations.
- Trial registration Number (ClinicalTrials.gov)
- NCT05577754

BMJ Open

1 2		
2 3 4	83	
5 6 7	84	Keywords:
7 8 9	85	Neurodevelopmental disorders, alpelisib, therapeutic trial, PIK3CA, MCAP
10 11 12	86	
12 13 14	87	Word count: 3822 words
15 16 17	88	
17 18 19	89	Strengths and limitations of this study:
20 21	90	• The SESAM trial is the first evaluation of alpelisib dedicated in patients with MCAP
22 23 24	91	using neurocognitive endpoints.
25 26	92	• The passage of alpelisib through the blood-brain barrier will be evaluated in the SESAM
27 28 29	93	trial.
30 31	94	The two-period design (double blind placebo-controlled period followed by open-label
32 33 34	95	period) has been chosen to comply with the best quality methodological standards.
35 36	96	 Heterogeneity in patient's clinical presentation represents a challenge in the
37 38 39	97	interpretation of the results.
40 41	98	No international consensus exists on the scales to be used in clinical trials in patients
42 43 44	99	with neurocognitive disorders.
45 46	100	
47 49		
40 49		
50		
51 52		
52 53		
54		
55		
56		
57 59		
50 59		
60		

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

101 INTRODUCTION

Segmental overgrowth disorders (SODs) are rare conditions usually characterized by abnormal and asymetric growth of some parts of the body. This excessive tissue growth is caused by an overactivation of the cell proliferation mechanism. Mosaic activating variants in the $p110\alpha$ catalytic subunit of phosphatidylinositol-3 kinase (PI3K; encoded by the PIK3CA gene) have been identified in a subset of SODs. The PI3K-AKT-mTOR is a critical signalling pathway in regulating proliferation, survival and cell growth. Activating variants in PIK3CA lead to increased PI3K-AKT-mTORC1 axis activation, which in turn promotes excessive growth in affected tissues [1-6].

The PIK3CA-related overgrowth spectrum (PROS) is a congenital condition with progressively asymmetric overgrowth which can begin in the antenatal period. This disease is wide-ranging, and depends upon the timing of the founder mutation in embryogenesis [6-9]. Depending on the clinical presentation (segmental body overgrowth or brain disorder), three main disease subgroups can be distinguished: the CLOVES syndrome (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/Skeletal/Spinal anomalies), the Klippel-Trenaunay syndrome and the MCAP syndrome (Megalencephaly Capillary malformation Polymicrogyria). CLOVES clinical presentation ranges from isolated digit enlargement to extensive overgrowth of limbs, thorax/abdomen and/or face. It may be accompanied by vascular or lymphatic malformations, epidermal nevi and spinal anomalies. Associated morbidity can be highly variable, but can include functional impairment, debilitating haemorrhages and thromboses, and, in some cases, can be lethal. For patients with Klippel-Trenaunay syndrome, vascular malformations are often in the foreground, associated with soft tissue and bone hypertrophy, and involve one limb, most often the lower limb. MCAP is

Page 9 of 36

BMJ Open

characterized by megalencephaly (large head), capillary malformation of the skin (middle face, limbs and trunk), abnormalities of the extremities and possible abnormalities of the brain structure (Chiari malformation, hydrocephalus, polymicrogyria) [9, 10]. Megalencephaly is present at birth, and the brain continues to develop gradually during the first postnatal years with a relative stabilization with age, although remaining larger than normal. MCAP patients may experience impaired cognition, hypotonia, variable intellectual deficiency and seizures. Abnormalities of the brain structure may be present (hydrocephalus, Chiari malformation and polymicrogyria in particular). Asymmetry of some body parts may also exist, as well as skin manifestations. Cardiac and genitourinary abnormalities have been reported in rare cases. The current diagnosis is established through a clinical evaluation and genetic testing on the affected tissues. In rare cases, the PIK3CA variant is present in all cells and not at a mosaic state. Magnetic resonance imaging (MRI) is used to identify and monitor brain abnormalities. The French National Protocol for Diagnosis and Care for MCAP syndrome [11] and an international expert consensus statement for standardizing care for individuals with PIK3CA-related disorders have been published [12]. As patients may be misdiagnosed, the true prevalence of the disease is not well known. But in France, in 2021, more than 60 MCAP patients had already been genotyped. Variability in the degree of neurocognitive manifestations is considerable, ranging from mild learning disabilities to profound intellectual disability, in some cases associated with epilepsy [10].

143 The natural history of PROS shows that most of the overgrowth progression occurs during 144 early childhood, emphasizing the need to assess the potential benefit of early treatment in 145 paediatric patients with PROS. It could avert associated complications and/or surgery by 146 decreasing disease progression at this active stage.

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

147	Interestingly, drug treatments that specifically inhibit the p110 $lpha$ catalytic subunit of PI3K have
148	been developed in oncology in case of tumors with <i>PIK3CA</i> gain-of-function variants. Alpelisib
149	(Vijoice [®] , Novartis Pharmaceutical) have been authorized in metastatic breast cancer [13, 14],
150	and has therefore been investigated through drug repurposing in PROS, in a case series of 19
151	French patients under a compassionate approach, including 2 with MCAP [15]. After
152	encouraging results in safety and efficacy, Novartis Pharmaceutical started the EPIK program.
153	The EPIK-P1 (NCT04285723) is a real-world study for demonstrating clinical benefit in people
154	with PROS, and EPIK-P3 (NCT04980833) a phase II study to assess long-term safety and efficacy
155	of alpelisib in people with PROS who participated in EPIK-P1. The ongoing international
156	prospective phase II double-blind, randomized, placebo-controlled study clinical trial (EPIK-P2,
157	NCT04589650), is assessing efficacy, safety and pharmacokinetics of alpelisib in pediatric and
158	adult patients with PROS. Positive preliminary results from EPIK-P1 led the FDA to grant early
159	April 2022, an accelerated approval for alpelisib (Vijoice®) in PROS, including MCAP, for
160	patients of 2 years of age and over, based on the efficacy (defined as a \geq 20% reduction from
161	baseline in the sum of measurable target lesion volume) observed in 37 patients from EPIK-P1
162	after 6 months of treatment [16]. However, these therapeutic studies preferentially targeted
163	patients with CLOVES or Klippel-Trenaunay syndromes, and endpoints were not designed to
164	assess neurocognitive improvement. Current data on alpelisib efficacy and safety in MCAP
165	patients solely comes from compassionate use, which fails to demonstrate a clear benefit of
166	the treatment on neurocognitive symptoms [15, 17]. There is even no proof that alpelisib
167	crosses the blood-brain barrier.
168	To assess the clinical benefit of Alpelisb in MCAP patients, it was necessary to construct a

clinical trial evaluating specifically neurocognitive functions. Based on the clinical and
 radiological evaluation of 33 French patients with MCAP syndrome [10], we designed the

BMJ Open

SESAM study to assess the safety and efficacy of alpelisib in these patients, and to assess its passage across the blood-brain barrier.

METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES

Study Setting

This study is promoted, partly funded, and coordinated by Dijon Bourgogne University Hospital. Drug supply and part of funding was supported by Novartis Pharmaceutical. It includes pediatric and adult patients covered by national health insurance. To minimize the logistic burden for the patients, inclusion and safety visits are performed in their local hospitals (9 sites in total). Two evaluating sites (Dijon Bourgogne University Hospital and Paris Necker Hospital) are in charge of the baseline and assessment visits.

Study design, participant, randomisation

Study design. The SESAM trial is a two-period multi-center Phase II trial, with 6 months double-blind, placebo-controlled period followed by an open label period (Figure 1). Patients and their legal representative are given by the investigator a consent form adapted to their age and ID severity (see supplemental material for the detailed consent forms) A separate and optional consent for lumbar puncture is also proposed. After validation of the screening exams at the inclusion visit, patients are randomized to take alpelisib (250mg/day for adults or 50mg/day for children) or placebo during 6 months, with a 1:1 ratio. A first evaluation will be performed at 6 months (secondary objective 1) to determine the response status and patients will be unblinded once the evaluation is done. Patients completing the double-blind phase will then be entered in an open-label phase as follows: patients on placebo will switch to alpelisib

BMJ Open

> (250mg/day for adults or 50mg/day for children), responders to alpelisib will continue alpelisib at same dose during 18 months, and non-responders will have their dose increased $(300 \text{ mg/day for adults}, 125 \text{ mg/day for children} \ge 6 \text{ years old only})$. Dose increase is not permitted for children aged 5 years and below. Non-responders are patients who did not experience sufficient clinical benefit (based on overall clinical response assessed by the investigator) and with no safety/tolerability concerns which may preclude from treatment continuation at higher dose level. Patients will undergo additional evaluation visits every 6 months, and a final evaluation visit after 24 months of alpelisib treatment (main objective). Patients will undergo a main evaluation visit with clinical, biological, functional and neurocognitive exams every 6 months. Safety monitoring will be assured on a monthly basis. The schedule and content of the visits are detailed in supplemental material (Annex 1a and 1b).

Participants. Patients aged 2-40 years, with documented evidence of postzygotic or 208 constitutional variant(s) in *PIK3CA* and a diagnosis of MCAP with a neurocognitive disorder 209 (from specific learning disorder to severe intellectual disability) at the time of consent could 210 be included. The main exclusion criteria are related to contra-indications to alpelisib 211 treatment such as history of pancreatitis, diabetes, or pneumonitis. The exhaustive list of 212 inclusion and exclusion criteria is detailed in annex 2 of the supplemental material.

Randomisation. Randomisation will be performed by the site staff using the centralized tool 215 in the e-CRF at baseline visit, only after confirming that the participant fulfills all the 216 inclusion/exclusion criteria. Investigator will have to confirm the key eligibility criteria 217 checklist embedded in the system to access to randomization tool in the e-CRF. A statistician

BMJ Open

3 4	218
5 6 7	219
7 8 9	220
10 11 12	221
12 13 14	222
15 16 17	223
18 19 20	224
20 21 22	225
23 24 25	226
26 27 28	227
29 30 31	228
32 33	229
34 35 36	230
37 38 39	231
40 41	232
42 43 44	233
45 46 47	234
47 48 49	235
50 51 52	236
53 54	237
55 56 57	238
58 59	239
00	240

218 from Dijon Bourgogne University hospital, independent of the research, will edit the 219 randomization list, prior to the start of the trial. Breaking of blinding can be requested by the 220 investigator for occurrence of serious adverse events requiring knowledge of the experimental product to determine the therapeutic course to be taken, by the unblinding function in the 221 randomization tool in the e-CRF. 222

Objectives 224

225 **Primary objective**

The primary objective is to assess the efficacy on adaptive behavior after 24 months of 226 227 alpelisib treatment.

Secondary objectives 228

To assess: (1) the efficacy of alpelisib vs placebo on adaptive behavior based on the 229 comparison of the proportion of participants with response at 6 months in each group, (2) the 230 impact of alpelisib treatment on cerebral and spinal cord vascularization and volume, (3) the 231 safety of alpelisib treatment. 232

234 **Exploratory** objectives

To evaluate the effects of algelisib on: (1) the early efficacy of algelisib on adaptive behavior, 235 236 (2) quality of life and clinical global impression, (3) neuropsychological parameters, (4) epilepsy, (5) overgrowth and skin lesions when appropriate, (6) hypotonia, and (7) to quantify 237 alpelisib passage throughout the blood-brain barrier and its relationship with systemic 238 exposure of alpelisib. 239

240

241 Study Endpoints

242 Primary outcome

According to the publication by Chatham et al. [18], clinically meaningful improvement will be defined as a gain of at least 4 points in the Vineland II Adaptive Behavior Scale (VABS-II) at 24 months of treatment compared to baseline. The VABS-II is the most widely used scale to assess day-to-day adaptive skills, from birth to adulthood [19, 20]. It consists of a form which will be filled during an interview with an adult who is familiar with the daily living activities of the patients (usually a parent). The VABS-II is organized within a three-domain structure: communication, daily living skills, and socialization. In addition, VABS-II has a motor skills domain for children younger than 6 years of age, and an optional maladaptive behavior index [19, 20]. The domain (communication, daily living skills, and socialization) standard scores have a mean of 100 and a standard deviation of 15. Adaptive levels can also be determined. A global standard score can also be computed (the Adaptive Behavior Composite standard score) and also has a mean of 100 and a standard deviation of 15.

255 Secondary outcomes

256 For the secondary objectives, the corresponding outcomes will include:

- (1) The response (yes/no) defined as an improvement of at least 4 points in the VABS-II at
 6 months of treatment in the alpelisib group compared to the placebo group.
- 259 (2) The changes in brain volume, vascularization, structural connectivity, assessed by MRI,
 - from baseline to end of treatment period.
 - (3) The number, type and severity of adverse events.

263 Exploratory outcomes

BMJ Open

2 3	264	Evelopeton, and a sinte will access the following.
4	264	exploratory endpoints will assess the following:
5 6 7	265	(1) Improvement of at least 4 points in the VABS-II at 6, 12, and 18 months of treatment,
8 9	266	compared to baseline.
10 11 12	267	(2) Evolution of quality-of-life questionnaires, scores at visual analogue scale, and
12 13 14	268	evolution of Clinical Global Impression of severity and Global improvement scores at
15 16	269	6, 12, 18, 24 months of treatment, compared to baseline.
17 18 19	270	(3) Changes in neuropsychological scales, adapted to age, at 12 and 24 months of
20 21	271	treatment compared to baseline for attention, cognition, visuo-spatial disorders, fine
22 23 24	272	motor skills, speech, reasoning and cognitive inhibition abilities, and at 24 months of
24 25 26	273	treatment compared to baseline for IQ scale.
27 28	274	(4) Description of changes in seizures frequency (weekly diary), and antiepileptic drugs
29 30 31	275	use at 6, 12, 18 and 24 months of treatment compared to baseline.
32 33	276	(5) Changes in overgrowth or skin lesions, classified as follows: increase, no changes or
34 35 36	277	reduction in overgrowth or skin lesions according to clinical measures and evaluation
37 38	278	of standardized photographs taken at 6, 12, 18 and 24 months of treatment compared
39 40 41	279	to baseline.
42 43	280	(6) Changes in MFM (Motor Function Measure) scores at 6, 12, 18 and 24 months of
44 45	281	treatment compared to baseline.
40 47 48	282	(7) Level of alpelisib (ng/mL) in cerebrospinal fluid (CSF) and in blood at between 6 or 24
49 50	283	months of treatment, and correlation estimate (rho) between CSF and blood levels of
51 52 53	284	alpelisib.
54 55	285	The versions of each scale or questionnaire according to age are detailed in figure 2.
56 57 58 59 60	286	Sample size calculation:

BMJ Open

> The assumptions are as follows: 1) when following untreated MCAP patients 6.0% at best may have experienced the 4 points improvement, 2) the minimal requirement for the treatment to be considered clinically relevant by regulatory bodies is at least one third of treated patients (33%) experiencing the 4 points improvement. With alpha = 0.05, 1-beta = 0.90 and a bilateral test, 16 patients are needed to prove statistical difference between the theoretical and observed proportion. We are thus planning to enroll and analyze 20 patients to take account of possible loss of follow-up or withdrawal of consent. The approach for sample size calculation is also pragmatic, based on known and estimated cohort. A cohort of about 60 patients with MCAP and PIK3CA pathogenic variant is available, two thirds of them having ID or learning disability that could justify being enrolled in a clinical trial. If a patient is withdrawn from the study before treatment initiation, he will be replaced, to be able to conduct the comparison between alpelisib and placebo groups with 10 patients in each group.

300 PATIENT AND PUBLIC INVOLVEMENT

The feasibility of recruitment is assured by the participation of experts in the clinical and molecular aspects of PROS, including the French reference center for mosaic disorders, the RHU COSY [21], and the French patient's association for MCAP (M-CM France).

305 DATA MANAGEMENT AND DATA ANALYSES

306 Data collection, monitoring and management

307 Clinical, biological and radiological data will be entered directly into a dedicated e-CRF 308 (electronic Case Report Form) on the CleanWEB platform by the investigators, helped by 309 Clinical Research Associate (CRA). The patient diary is paper-based and will be reviewed by

BMJ Open

the investigator to capture the safety events that will be entered in the e-CRF. Each patient is identified by a unique code including: the number of the recruiting center, the inclusion rank, the initials of the patient (first letter of surname and first name). Automatic gueries due to missing and incoherent data after data entry can be immediately generated by the CleanWEB software. Requests for corrections may also be generated by the methodological support unit of CHU Dijon and sent to the local and/or the evaluation center. The corrections will be made directly in the e-CRF by the investigators, assisted by the CRAs. Histories of changes are systematically recorded. Additionally, a CRA will perform an on-site exhaustive data monitoring for all patients. A data management plan, specific to the study, was prepared before initiating the study in the participating centers.

321 Statistical Analyses

322 Descriptive analysis

Descriptive analysis with presentation of the baseline characteristics of the cohort, with qualitative variables expressed as number of events with their frequencies (%), with their 2sided exact 95% confidence interval (CI). For quantitative variables, mean (±SD) or median (IQR) values will be calculated.

327 Primary outcome analysis

Fisher's exact test or chi square test will be used to compare the observed proportion of patients reaching the primary endpoint after 24 months of treatment to the theoretical proportion of 6%. A p<0.05 will be considered significant.

331 Secondary analyses

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

The same approach will be used to compare the proportion of responders at M6 between alpelisib and placebo groups. Comparison of brain volumes (affected and unaffected zones) at after 24 months of treatment versus baseline will be performed using a paired-t-test or Wilcoxon rank test according to the distribution priorly assessed by a Shapiro-Wilk test.

For all safety analyses, data recorded during monitoring for adverse events (AE), either clinical or biological, will be collated and the number, type grade of AE, and their relation to treatment, will be described and the frequencies of AEs recorded as percentages and 95% CI. Results will be presented for the overall 24-month-period of treatment, and also specifically for the double-blind period, to compare safety between alpelisib and placebo. The CTCAE (v5.0) classification will be used to grade the events.

343 Exploratory analyses

Comparison of the mean scores of neuropsychological scale scores obtained at baseline and M24 will be performed using a paired-t-test or Wilcoxon rank test. To test the reliability of the change, the Reliable Change Index (RCI) will be calculated for each psychometric scale [22]. For fine reasoning and cognitive inhibition abilities, the raw data (logfiles from Presentation software) will be analyzed automatically using Matlab 7.1. A Reaction Time (RT) and an Error Rate (ER) analysis will be performed using R software (see supplemental material – Annex 3). Change in scores at the MFM test will be assessed by analyzing the slopes of change between scores obtained at 6, 12, 18 and 24 months of treatment vs. baseline for each patient, and expressed as an annual rate using the unweighted least-square estimate. Comparison of mean scores will then be performed using a paired-t-test or Wilcoxon rank test.

Finally, the correlation between CSF level and blood level of alpelisib will be estimated by
 calculating the factor rho of Spearman's correlation.

-		
2		
5 4	356	
5		
6	357	Statistical Software
7		
8	358	Analysis will be performed using SAS software (version 9.4) Statisticians will be blinded to the
9 10	550	
10	320	study
12	333	Study.
13	260	
14	300	
15	361	METHODS: MONITORING
16 17		
17	262	Harma Staaring data and cafety monitoring committees
19	302	Harms. Steering data and safety monitoring committees
20		
21	363	The coordinating centre at University Hospital Dijon-Bourgogne, Clinical Investigation Centre
22		
23	364	(CIC INSERM 1432), is assigned the responsibility of all study aspects: ethical, regulatory, study
24 25		
26	365	coordination, data management and publication strategy.
27		
28	366	The steering committee is composed by the coordinating investigator a methodologist a
29	300	
30 21	267	pharmacovigilance officer, a pharmacist, a sponsor representative, and the project manager
31 32	307	pharmacovignance onicer, a pharmacist, a sponsor representative, and the project manager.
33	260	This committee meets on a weekly basis to access study progress and solve potential issues
34	308	This committee meets on a weekly basis to assess study progress and solve potential issues.
35	260	An independent data as fature with rise based (DCLAD) is monitorize the matients/ as fature during
36	369	An independent data safety monitoring board (DSIVIB) is monitoring the patients' safety during
37		
20 20	370	the study and gives recommendations to the steering committee. It is composed of a
40		
41	371	pharmacologist or pharmacovigilant officer, a metholologist, a neuropediatrician, and a
42		
43	372	geneticist. The DSMB met when the first 4 included patients (25% of the initially anticipated
44 45		
45 46	373	number of patients) had completed 1 month of treatment, and will meet again at 50% and
47		
48	374	75% of the inclusions. Treatment initiations will be halted at each threshold and will resume
49		
50	375	after review of the safety data by the DSMB.
51		
52 53	376	
54	0.0	
55		
56	377	ETHICS AND DISSEMINATION
57		
58		
48 49 50 51 52 53 54 55 56	374 375 376 377	75% of the inclusions. Treatment initiations will be halted at each threshold and will resume after review of the safety data by the DSMB.

BMJ Open

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Authorization was obtained from the French National Drug Safety Agency on 28/07/2022 and from the Ethics Committee (CPP Sud-Ouest et Outre-Mer I) on 22/09/2022 (reference number: 2022-500197-34-01). The protocol was registered with ClinicalTrials.gov under the identifier NCT05577754 in 13/10/2022. Current version of protocol is V3 (25/05/2023). The first patient was included in November 2022 and the study is expected to be completed by April 2026.

Results will be presented at scientific meetings and published in international peer-reviewed journals.

DISCUSSION

At present, there is no licensed or unlicensed drug with a proven benefit for patients with MCAP syndrome, although alpelisib FDA's approval for patients with PROS, based on collection of real-world evidence from compassionate use, makes it possible to treat patients with MCAP syndrome. As such, there is a clear unmet medical need. The understanding of the pathophysiology of the PROS and MCAP syndromes, a *PIK3CA* gain-of-function variant, and the development of specific PI3K3 inhibitors in cancer, where the same variants are found, has raised great hopes of eventually providing an effective treatment.

Whereas Novartis Pharmaceutical's sponsored EPIK-P2 is running for patients with PROS, no such study was planned for patients with MCAP syndrome. Even if the data are sparse, Venot et al. reported that the two patients with MCAP syndrome among the 19 patients with PROS syndrome, exhibited improvement in cognitive function, behavior, and cerebral perfusion [15]. We therefore hypothesized that alpelisib treatment could be useful for these patients and designed a dedicated trail.

Page 21 of 36

BMJ Open

The judgement criteria for the SESAM study were based on the collection of complete clinical
and radiological data from 33 French patients, which we published in 2021 [10]. It was this
cohort that led us, for example, not to adopt the evolution of epileptic seizures as the primary
endpoint, as only 10% to 15% of patients suffer from them.
We chose VABS as the primary endpoint, as it has been evaluated in clinical trials on
neurodevelopmental disorders, to assess the changes experienced by patients/families in
their daily lives [18]. Nevertheless, in the absence of national or international consensus on
the scales to be used in clinical trials aimed at demonstrating an improvement in patients with
neurocognitive disorders, we have chosen to use a battery of scales, all addressing
complementary domains, appropriate to the age, cognitive level, ability of the patients to
concentrate, and the time constraints between two assessments. We believe that the results
of this trial will provide useful information for future clinical trials targeting
neurodevelopmental pathologies. We added a simplified paradigm matrix stimuli especially
designed by the expert team to try to identify fine points of improvement in clinical trials that
would be difficult to demonstrate with conventional scales [23]. Although we have no
certainty about the possibility of achieving a reduction in brain volume, we felt it is important
to assess this. Therefore, volumetric MRI will be performed at the beginning of the study and
at the end of the treatment. Given the poor knowledge of the prevalence of spinal cord
abnormalities in MCAP, spinal cord MRI was added to the protocol. Assessing quality of life as
well as the effect of alpelisib on other non-brain manifestations of the disease were also
planned.

and radiological data from 33 French patients, which we published in 2021 [10]. s this cohort that led us, for example, not to adopt the evolution of epileptic seizures as the mary endpoint, as only 10% to 15% of patients suffer from them. We chose VABS as the primary endpoint, as it has been evaluated in clinica ls on neurodevelopmental disorders, to assess the changes experienced by patients/ es in their daily lives [18]. Nevertheless, in the absence of national or international con us on the scales to be used in clinical trials aimed at demonstrating an improvement in pa with neurocognitive disorders, we have chosen to use a battery of scales, all ssing complementary domains, appropriate to the age, cognitive level, ability of the its to concentrate, and the time constraints between two assessments. We believe that sults of this trial will provide useful information for future clinical trials eting neurodevelopmental pathologies. We added a simplified paradigm matrix stimuli cially designed by the expert team to try to identify fine points of improvement in clinica that would be difficult to demonstrate with conventional scales [23]. Although w e no certainty about the possibility of achieving a reduction in brain volume, we felt it is rtant to assess this. Therefore, volumetric MRI will be performed at the beginning of the y and at the end of the treatment. Given the poor knowledge of the prevalence of s cord abnormalities in MCAP, spinal cord MRI was added to the protocol. Assessing quality ife as well as the effect of alpelisib on other non-brain manifestations of the disease also planned. The passage of alpelisib through the blood-brain barrier has only been hypothesized, based

or an improvement in epileptic seizures. It is therefore necessary to assess and quantify the

on the observation of a reduction in the size of brain metastases in women with breast cancer

BMJ Open

passage of alpelisib into the cerebrospinal fluid (CSF), in relation with the plasmatic dosage. This will help to establish a correlation between the plasma concentration and that of the CSF, possibly allowing therapeutic monitoring on the basis of plasma concentrations alone [24]. The SESAM trial also benefits from the accumulated experience of our previous trials, one with mTOR inhibitor sirolimus, and the other with taselisib, another PI3K α -specific inhibitor [25, 26]. In particular, conducting this trial as part of a well-established network with investigators from local centres, enabling some of the follow-up visits to be carried out close to patients' homes, improves acceptability and ensures that the trial runs smoothly. In addition, by using this two-period design which allows all patients to be treated, we aim to demonstrate that a rigorous methodology can be applied in clinical trials in rare diseases, with high quality standards while preserving the acceptability of the trial's burden for the patient. Based on our preliminary data in CLOVES, we will enhance knowledge relating to the efficacy and side-effect profile associated with long-term treatment with PI3K pathway inhibition, and determine the effectiveness of treatment across an expanded number of PROS. Considering the pathological overlap deriving from the common feature of *PIK3CA* upregulation, our work may also inform future transversal therapeutic strategies in the context of a larger group of diseases. DATASHARING All requests for the study's data will be considered by the SESAM trial steering committee. **TRIAL STATUS**

2 3 4	447	Recruitment is completed (last patient included in May2024) and follow-up is ongoing until
5	448	April 2026.
7 8 9	449	
10 11	450	
12 13 14	451	
15 16		
17 18 19		
20 21		
22 23 24		
25 26		
27 28 29		
30 31		
32 33 34		
35 36 27		
37 38 39		
40 41 42		
42 43 44		
45 46 47		
48 49		
50 51 52		
53 54		
55 56 57		
58 59		
60		

REFERENCES

Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, et al. Mosaic overgrowth 1. with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet. 2012;44(8):928-33.

2. Rivière JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012;44(8):934-40.

3. Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 2012;90(6):1108-15.

4. Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, et al. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet. 2013;22(3):444-51.

Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 5. 2008;27(41):5486-96.

6. Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T, et al. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med. 2017;19(9):989-97.

Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, et al. 7. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A. 2014;164a(7):1713-33.

Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, et al. PIK3CA-8. related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167a(2):287-95.

Mirzaa GM, Rivière JB, Dobyns WB. Megalencephaly syndromes and activating 9. mutations in the PI3K-AKT pathway: MPPH and MCAP. Am J Med Genet C Semin Med Genet. 2013;163c(2):122-30.

10. Garde A, Guibaud L, Goldenberg A, Petit F, Dard R, Roume J, et al. Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials. Clin Genet. 2021;99(5):650-61.

11. Haute Autorité de Santé Procotole; National de Diagnostic et de Soins for MCAP https://www.has-sante.fr/upload/docs/application/pdf/2021-10/pnds-[Available from: mcap_sept_2021.pdf.

12. Douzgou S, Rawson M, Baselga E, Danielpour M, Faivre L, Kashanian A, et al. A standard of care for individuals with PIK3CA-related disorders: An international expert consensus statement. Clin Genet. 2022;101(1):32-47.

BMJ Open

13. Arafeh R, Samuels Y. PIK3CA in cancer: The past 30 years. Semin Cancer Biol. 2019;59:36-49.
14. Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-40.
15. Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540-6.
16.Food and Drug Administration - FDA approves alpelisib for PIK3CA-related overgrowth spectrum 2022 [updated 04/06/2022. Available from: https://www.fda.gov/drugs/resources- information-approved-drugs/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum.Image: Comparison of the spectrum of the spectru
17.Morin G, Degrugillier-Chopinet C, Vincent M, Fraissenon A, Aubert H, Chapelle C, et al.Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. J Exp Med.2022;219(3).
18. Chatham CH, Taylor KI, Charman T, Liogier D'ardhuy X, Eule E, Fedele A, et al. Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II. Autism Res. 2018;11(2):270-83.
19. Sparrow SS, Balla, D. A., & Cicchetti, D. V Vineland adaptive behavior scales: Interview edition, survey form manual. Circle Pines, MN: American Guidance Service. 1984.
20. Sparrow SSC, D.V.; Saulnier, C.A. Vineland-3: Vineland Adaptive Behavior Scales. 3rd ed. Pearson Assessments; Minneapolis, MN, USA. 2016.
21. Recherche Hospitalo Universitaire (RHU) - Cure Overgrowth Syndromes (COSY) [Available from: https://rhu-cosy.com/.
22. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12-9.
23. Curie A, Brun A, Cheylus A, Reboul A, Nazir T, Bussy G, et al. A Novel Analog Reasoning Paradigm: New Insights in Intellectually Disabled Patients. PLoS One. 2016;11(2):e0149717.
24. Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM. Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib. JCO Precis Oncol. 2020;4.
25. Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet Med. 2019;21(5):1189-98.
26. Luu M, Vabres P, Devilliers H, Loffroy R, Phan A, Martin L, et al. Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay

BMJ Open

syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study. Genet Med. 2021;23(12):2433-42.

FULL LIST OF CO-INVESTIGATORS OF THE SESAM STUDY GROUP

Dr Benedicte Demeer (CHU Amiens) ; Dr Estelle Colin (CHU Angers) ; Dr Elise Boucher-Brischoux (CHU Besançon) ; Adélaïde Brosseau-Beauvir (CHU Brest) ; Dr Christine Francannet (CHU Clermont Ferrand); Dr Florian Cherik (CHU Clermont Ferrand); Pr Jean-Marc Treluyer (CHU Cochin); Pr Florence Petit (CHU Lille); Pr Alice Phan (CHU Lyon); Dr Michaela SEMERARO (Necker AP-HP); Dr Marion Nys (Necker AP-HP); Dr Charles Joris Roux (Necker APHP); Dr Philippe Khau Van Kien (CHU Nimes) ; Dr Alinoë Lavillaureix (CHU Rennes) ; Pr Isabelle Maruani .2.1.04 (CHRU Tours);

AUTHORS' CONTRIBUTIONS :

Maxime LUU (ML) is the guarantor for the overall content. LF and PV initiated this study. LF, ML, MB designed the study. ML has written this manuscript. LF, MB, AM, AE, AG, CR, AR, RL, NH, NB, AC, LG, MC, PK, JC, GC, NBH, AC, MC and CF (sponsor), and Novartis Pharmaceuticals (sponsor) reviewed the manuscript. All authors read and approved the final manuscript.

FUNDING

This study was co-funded by Novartis Pharmaceutical and the University Hospital of Dijon Bourgogne.

3 4	569
5 6	570
/ 8 9	571
10 11	572
12 13 14	573
15 16	574
17 18	575
19 20 21	576
22 23	577
24 25 26	578
27 28	579
29 30	580
31 32 33	581
34 35	582
36 37 38	583
39 40	584
41 42 43	585
44 45	586
46 47	587
48 49 50	588
51 52	589
53 54 55	590
56 57	
58 50	
59 60	

569	CONFLICTS OF INTEREST
570	A patent application ("BYL719 (alpelisib) for use in the treatment of PIK3CA-related
571	overgrowth spectrum" #WO2017140828A1) has been filed by INSERM (Institut National de la
572	Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS),
573	Université Paris Cité, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719
574	(alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS/CLOVES
575	syndrome). Dr. Canaud is the inventor. This patent is licensed to Novartis Pharmaceutical.
576	
577	ML has received consulting fees from Novartis Pharmaceutical. GC receives or has received

consulting fees from Novartis Pharmaceutical, Fresenius Medical Care, Vaderis, Alkermes, 578 579 IPSEN and BridgeBio.

LEGENDS 582

Figure 1. Study design of the SESAM trial 583

Figure 2. Neuropsychological tests used in the SESAM trials. Tests were selected according to 585 the conclusions of a working group from the DéfiScience Network (www.defiscience.fr), which 586 assessed all the neuropsychological tests available for each domain and adapted to ID 587 588 patients. The 20-item Motor Function Measure (MFM20) will be administered for children <7 yo, and the MFM32 for children \geq 7yo. 589

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

MCAP_study plan 18 01 2023



L : visit at local site : C : visit at coordinating site : P: Phone visit by coordinating site : V-FUp : Follow-up visit 30 days after end of treatment Safety call (monthly)

+ Quarterly Dispensation

Figure 1. Study design of the SESAM trial

254x190mm (300 x 300 DPI)



Figure 2. Neuropsychological tests used in the SESAM trials. Tests were selected according to the conclusions of a working group from the DéfiScience Network (www.defiscience.fr), which assessed all the neuropsychological tests available for each domain and adapted to ID patients. The 20-item Motor Function Measure (MFM20) will be administered for children <7 yo, and the MFM32 for children ≥7yo.

338x190mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2024-084614 on 20 December 2024. Downloaded from http://bmjopen.bmj.com/ on May 20, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

SUPPLEMENTAL MATERIAL

Annex 1a Assessment Schedule for Group A : patients allocated to placebo during double-blind period

Annex 1b. Assessment Schedule for Group B : patients allocated to alpelisib during double-blind period

Annex 2. Complete list of inclusion and exclusion criteria

, inclusion , or visual analogi. Annex 3. Computer task for visual analogical reasoning paradigm

Page 31 of 36

BMJ Open

Annex 1a. Assessment Schedule for Group A : patients allocated to placebo during double-blind period

l of 36	la far Cr		ationto all	lacatad	to place	aha d	BN	IJ Open	ind nor	ind			bmjopen by copyr						
Annex 10. Assessment Schedu	ie jor Gr	oup A : p	utients dil		το ριάζ	eno a	uring	uoubie-bi	ma per	100			-202. ight,	and a dealer at the					
Period		Screening	L		i period : Pi		reatment	MC	MOUNT	MCION	1 147	1 140		Deriod: AL	PELISIB treat	ment	L 1424	M 07	L 1420
treatment duration		max 3 m	DU	VV I	VV2	MI	M 3	MB	1w	2w	1m	3 m		MB	12 m	MZI	18 m	M 27	M 30
	Visit 0	Visit 1	Visit 2	[1	1	1	Visit 7											Visit 18
Visit Name				Vicit 3	Vicit 4	Vicit 5	Visit 6	Interim	Vicit 8	Vicit 0	Vicit 10	Vicit 11	ii 14	Vicit 13	Visit 14	Vicit 15	Visit 16	Vicit 17	End of
	Information	Inclusion	Baseline	VISICO	VISIC 4	VISIC O	VISICO	evaluation	VISICO	VISICO	VISIC TO	VISIC 11		1	VISIC 14	VISIC 10	VISITIO	VISICIT	treatment
		-						Baseline					<u>q</u>				-		(EOT)
Week	<w-12< td=""><td>W-12 to D-1</td><td>D0 to D2 or D3</td><td>W1</td><td>W2</td><td>W4</td><td>W12</td><td>W24</td><td>W25</td><td>W27</td><td>W28</td><td>W36</td><td>c W520</td><td></td><td>W72</td><td></td><td>W104</td><td></td><td></td></w-12<>	W-12 to D-1	D0 to D2 or D3	W1	W2	W4	W12	W24	W25	W27	W28	W36	c W520		W72		W104		
Site	Assessment	Local	Assessment	Phone call	Local	Local	Local	Assessment	Phone call	Local	Local	Local	Amsesse	nt Local	Assessmen	t Local	Assessmen	t Local	Assessmer
													S C	± 14		± 14		± 14	
Window s allow ed				±1 days	±2 days	±7 days	±7 days	±7 days	±1 days	± 2 days	±7 days	±7 days	e 11 7 da@as	days	± 14 days	days	± 14 days	days	± 14 days
Informed Consent	Information	•											nb Er:						
nclusion/exclusion criteria	•	•											ec ar						
Demography		•											438						
Medical and surgical history		•											3 2 2						
Non drug theranies/surgical /medical													857						
non drug therapies/surgical/medical		•							Continuous	up to 30 day	s after the	e last dose		atment					
									Continuous	up to 30 day	s after the	last dose		atment					
		•				—		<u> </u>		ap 10 00 aa,					-	T -	<u> </u>		
Physical examination		•	•		•	•	•	•		•	•	•		•	•	•	•	•	•
Vital Signs		•	•		•	•	•	•		•	•	•	<u> </u>	•	•	•	•	•	•
Visual Analogue Scale			•					•					<u>⊐</u> Ω				•		•
Electrocardiogram (EKG)		•	•					•		•	•		lii•∓		•		•		•
Digital Photography of affected areas			•					•					on • in		•		•		•
Measurements of hypertrophic areas			•					•					а, ,						•
Brain MRI			•										A 🛓						•
Spinal cord MRI •			•						_				5						•
Blood sample		•	•	•	•	•	•		•	•	•	•	<u>≅</u>	•	•	•	•	•	•
				1									3	-			-		
							•					-	<u>e</u> <u>e</u>	-	-				-
											<u> </u>								
Pregnancy test*		•	•			•	•	•			•	•		•	•	•	•	•	•
One optional lumbar puncture + blood	optional												s s						
sample for alpelisib dosages	consent														•		•		•
between 6 to 24months of treatment													<u>=: </u>	_			-		
VABS-II			•					•					N • 3		•		•		•
Wechsler scale and profil** /***			•										đo						•
Revised Brunet-Lézine scale ***			•										S D						•
NEPSY-II ***			•										n N		•				•
CMS/MEM***			•										ੱੱ		•				•
CGI-S and CGI-I			CGI-S					•					20 gi		•		•		•
Fine reasoning and inhibition abilities			•					•					\$ • N		•		•		•
QoLquestionnaire ***		1	•					•			1	İ	- <u>.</u>		•	Ī	•	T	•
MEM scale			•					•			1	1	 		•	1	•	1	•
Randomisation			-										<u> </u>		+	1	+	+	⊢ –
				<u> </u>			<u> </u>	-				-	<u> </u>	-	<u> </u>	-	+ -	+ -	
			•				-					-		-		-		-	
wonitoring post first administration			auring 30mins	├ ───		<u> </u>		auring somins			 	 	<u>ja</u>			<u> </u>			
Education of guardians on clinical			•			1		•					l st				1		
signs of alpelisib toxicity/overdos		<u> </u>			ļ		ļ	 	ļ	ļ	<u> </u>						<u> </u>		ļ
Unblinding data								 post evaluation 					n n			1			
Epilepsiy daily diary			ļ							daily dia	ry complet	ed by pat	ient 🖸						
Medical diary										dailv dia	ry complet	ed by pat	ient N						
daily dosing and any AE experienced											,	pat							
Adverse events		•†	•	•	•	•	•	•	•	•	•	•	• –	•	•	•	•	•	•

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Annex 1b. Assessment Schedule for Group B : patients allocated to alpelisib during double-blind period

		_				BM.	J Open				by copy					
Annex 1b. Assessment Schedule	: for Grou	ıp B : pa	tients alloca	ted to a	lpelisib	during	double-	blind period	d 		right, i	2002				
Period	4	Screening	DA	Double-blin	a perioa : A		eatment	MC	MO	U	pe n s-labe	period: ALPE	LISIB treatm	ient Maa	-	
treatment duration		max 3 m	DU	1w	2w	1m	3 m	6 m	M 9	12 m		18m	21m	24m		
Visit Name	Visit 0	Visit 1 Inclusion	Visit 2 Baseline	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7 Interim	Visit 8	Visit 9	ding f	Visit 11	Visit 12	Visit 13 End of treatment		
Week	<w-12< td=""><td>W-12 to D-</td><td>D0 to D2 or D3</td><td>W1</td><td>W2</td><td>W4</td><td>W12</td><td>W24</td><td></td><td>W52</td><td></td><td></td><td></td><td>(EOT) W104</td><td>+</td></w-12<>	W-12 to D-	D0 to D2 or D3	W1	W2	W4	W12	W24		W52				(EOT) W104	+	
Site	Assessment	Local	Assessment	Phone call	Local	Local	Local	Assessment	Local	Assessment		Assessment	Local	Assessment	t	
Windows allowed	I			± 1 days	±2 days	±7 days	±7 days	±7 days	±7 days	±7 days	0 ^{± 14}	± 14 days	± 14 days	± 14 days	T	
Informed Consent	Information	•										3				
	•	•	\sim								<u> </u>	1			╈	
Demography	<u> </u>	•									<u>555</u>	1			╈	
Medical and surgical history	<u>├</u> ────	•									i a s f	1			╈	
Non drug theranies/surgical/medical	├ ────					1		1	1	1	<u>lằĝ</u> ,		1	1	1	
procedures	ļ'	•					Continuous	up to 30 days afte	r the last dos	se of study tre						
Concomitant medications	 '	•					Continuous	up to 30 days afte	r the last dos	se of study tre		-				
Physical examination	ļ'	•	•		•	•	•	•	•	•	<u> </u>	<u> •</u>	•	•	╞	
Vital Signs	ļ'	•	•			•	•	•	•	•		•	•	•	4	
√isual Analogue Scale	 '		•					•		•	╎╡╴╴	•		•	╇	
Electrocardiogram (EKG)	ļ'	•	•	ļ	•	•		•		•		•		•	_	
Digital Photography of affected areas	Ļ'		•					•		•	g	•		•		
Measurements of hypertrophic areas	ļ'		•	ļ				•						•	_	
3rain MRI	ļ'		•											•		
Spinal cord MRI •	ļ'		•					▶ _			ai	<u> </u>		•		
3lood sample	ļ'	•	•	•	•	•	•	•	•	•	11.0	•	•	•		
HbA1C	ļ'	•					•		•	•	jo s	•		•		
Hepatitis and HIV		•									a 3					
Pregnancy test*		•	•			•	•	•	•	•	nd •	•	•	•		
One optional lumbar puncture + blood sample for alpelisib dosages between 6 to 24months of treatment	optional consent							•	C	•	simila	•		•		
VABS-II			•					•		•	T.	•		•		
Wechsler scale and profil** /***			•								eo			•	Ι	
Revised Brunet-Lézine scale ***			•								hr			•	Ι	
NEPSY-II ***			•							•	ol			•	Ι	
CMS/MEM***			•							•	<u>60</u>			•	Ι	
CGI-S and CGI-I			CG⊦S					•		•	ie,	•		•	Ι	
Fine reasoning and inhibition abilities			•					•		•	ŝ.	•		•	Ι	
QoLquestionnaire ***			•					•		•	Ň	• •		•		
MFM scale			•					•		•	٩	•		•	T	
Randomisation			•													
Study Drug Dispensation			•				•	•	•	•	• 4	•	•			
Monitoring post first administration			●during 30 min								<u> </u>				Τ	
Education of guardians on clinical	<u> </u>	İ		1						1	1 5	i i			╈	
signs of lithium toxicity/overdos			•					•			a					
Unblinding data		1						•post evaluation			-	1			T	
Epilepsiy daily diary						•		daily diary cor	npleted by pa	atient	G		•			
Medical diary	<u> </u>	İ						della d'ann	minte di buc	tiont	- h	1				
daily dosing and any AE experienced	ļ'		• •													
Adverse events		• [†]	•	•	. • .	. •	•	•	•	•	• >	* •	•	•	1	

children: Control of the contro
Annex 2. Complete list of inclusion and exclusion criteria

- 1. Signed informed consent and assent (when applicable) from the patient, parent, or guardian must be obtained prior to any study related screening procedures are performed.
- 2. Male or female patients age \geq 2 years and \leq 40 years at the time of informed consent
- 3. Patients with diagnosis of MCAP* with neurodevelopmental disorder presentation (from specific learning disorder to severe intellectual disability) The most recent set of diagnostic criteria for MCAP includes five core features: progressive megalencephaly (criterion 1), developmental vascular disorders (criterion 2), distal limb anomalies (criterion 3), cortical brain malformations (criterion 4), connective tissue dysplasia (criterion 5) plus supportive features. MCAP syndrome is diagnosed in the presence of criterion 1 plus either criterion 2 or criterion 3 (Mirzaa et al., 2013). The absence of
- criterion 2 and 3 can be accepted in constitutional variant.
 4. Documented evidence of a somatic or constitutional mutation(s) in the PIK3CA gene performed in local laboratories using a Deoxyribonucleic acid (DNA) based validated test at the time of informed consent.
- 5. Adequate bone marrow and organ function (assessed during the screening visit):
 - a. Absolute neutrophil count ≥ 1.5 × 109/L
 - b. Platelets $\geq 100 \times 109/L$
 - c. Hemoglobin \ge 9.0 g/dL (transfusions are allowed)
 - d. Calcium (corrected for serum albumin) and magnesium within normal limits or ≤Grade 1 according to NCI-CTCAE version 5.0 if judged clinically not significant by the investigator
 - e. Potassium within normal limits.
 - f. INR ≤1.5
 - g. Creatinine Clearance ≥ 30 mL/min using Modification of Diet in Renal Disease (MDRD) (≥18 years old) or creatinine-based Bedside Schwartz (<18 years old) Glomerular filtration rate (GFR) equation
 - h. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \leq 2.5 × ULN.
 - i. Total bilirubin< ULN except for patients with Gilbert's syndrome who may only be
 - j. Fasting plasma glucose (FPG) ≤ 140 mg/dL (7.7 mmol/L) and Glycosylated hemoglobin (HbA1c) ≤ 6.5% (both criteria have to be met)
 - k. Fasting Serum amylase $\leq 2 \times ULN$
 - I. Fasting Serum lipase ≤ ULN
- 6. Able to swallow study drug according to age: tablets, or as drinkable suspension, or granules (under development)
- 7. For women of child-bearing potential only: negative pregnancy test at screening visit
- 8. Male patients with sexual partners who are pregnant, possibly pregnant or who could become pregnant should use condoms during sexual intercourse for the duration of the study and for one week following discontinuation of alpelisib.
- 9. For exploratory study only: signed informed optional consent for lumbar puncture

EXCLUSION CRITERIA

Participants meeting any of the following criteria are not eligible for inclusion in this study:

- 1. Patient previously treated with alpelisib
- 2. Known impairment of GI function due to concomitant disease that may significantly alter the absorption of the study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) at time of informed consent.
- 3. Participant with uncontrolled diabetes mellitus (Type I or II) at time of informed consent.
- 4. History of hypersensitivity to any drugs or metabolites of PI3K inhibitor or any of the excipients of alpelisib at time of informed consent.
- 5. Participant with other concurrent severe and/or uncontrolled medical conditions that would, in the treating Physician's judgment, contraindicate administration of alpelisib (e.g., active and/or uncontrolled severe infection, chronic active hepatitis, hepatic impairment Child Pugh score C, immuno-compromised, etc.) at time of informed consent.

6.	Female participants of childbearing potential and male participants who do not agree at t
	of informed consent to abstinence or, if sexually active, unwilling to use a condom and/
	highly effective method of contraception for the duration of the study and for one w
	following discontinuation of alpelisib. Highly effective contraception methods is one of
	following:
	a. Total abstinence: when this is in line with the preferred and usual lifestyle of the sub
	Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods)
	b Female sterilization: have had surgical bilateral conhorectomy (with or without hysterecto
	total hysterectomy or bilateral tubal ligation at least six weeks before taking alpelisib. In
	of oophorectomy alone, only when the reproductive status of the female has been confir
	by follow-up hormone level assessment
	c. Male sterilization at least 6 months prior to screening. The vasectomized male partner sh
	be the sole partner for that study participant d. Use of oral, injected or implanted horm
	methods of contraception or placement of an intrauterine device or intrauterine system
	other forms of hormonal contraception that have comparable efficacy (failure rate <1%)
	If local regulations deviate from the contracention methods listed above to provent
	programsy local regulations apply and will be described in the ICE
7	Treatment by any mTOR or PI3K-AKT signaling nathway inhibitor within 1 monthhefore
/.	inclusion
8.	History of prior and or ongoing malignancy (within 5 years before informed consent excer
0.	radically treated Carcinoma in situ of radically treated basal-cell carcinoma of skin or thyr
	gland well differentiated microcarcinoma or Stage 1 Wilms' tumor of a histology other that
	anaplastic), or ongoing investigations or treatment for malignancy at time of informed
	consent.
9.	Treatment with strong inducers of CYP3A4 and inhibitors of Breast Cancer Resistance Pro-
	(BCRP) that cannot be stopped at least the week prior to the screening
10.	Debulking or other major surgery performed within 3 months at time of informed consen
11.	Known history of Steven Johnson's syndrome, erythema multiform or toxic epidermal
	necrolysis at time of informed consent.
12.	For participants ≥ 6 years of age: Participants with documented pneumonitis or interstitia
	lung disease at the time of informed consent and with impaired lung function (e.g., FEV1
	(Forced expiratory volume) or DLCO (Diffusing Capacity of the Lung for Carbon Monoxide
	70% of predicted) that is not related to PROS.
13.	For participants between 2 to 5 years of age: Participants with documented or suspicious
	pneumonitis or interstitial lung disease based on MRI images at time of informed consent
14.	History of acute pancreatitis within 1 year before informed consent or past medical histor
	chronic pancreatitis at time of informed consent.
15.	Clinically significant heart disease at time of informed consent, including:
	a. History of documented congestive heart failure (New York Heart Association functional
	classification III-IV)
	b. Clinically significant uncontrolled cardiac arrhythmias c. Long OT cyndromo, family history of idiopathic syddon doath or congenital long OT cyndro
	d Corrected OT (OTCE) at screening: >470 ms for >18 years old / >450 ms for <18 years old
	e Creatinine clearance < 70 ml/min/1 73 m ²
16	Patient currently, or in the 3 months before inclusion, enrolled in another interventional t
17	Person not affiliated to a national health insurance scheme
18.	Patient, parents or legal authorized representative incapable of expressing consent
	Inability to attend all trial visits
19.	
19. 20	For the optional lumbar puncture only : known intracranial hypertension active infection

Annex 3. Computer task for visual analogical reasoning paradigm

Simple Matrices task

1 2 3

4 5

6 7

8

9

10

11

12

13 14

15 16

17 18

19

20

21

32

33

42

43

44 45

46 47

48

49 50

51

52

53

54 55

56 57

58

59 60 The simplified paradigm matrix stimuli especially designed by the expert team consist of four elements (instead of the nine cells in Raven's), with two response choices (instead of the eight in Raven's). Four parameters are involved in matrix creation: color (white, black or grey), form (round, square or triangle), number (one or two), and size (large or small). The number of relations between the items that need to be considered jointly to find the correct answer define the relational complexity of a matrix.

There are three levels of complexity:

- Identical: the three elements of the matrix are the same (Figure 1a);
- "One-relation" (Figure 1b): a very simple reasoning that requires consideration of only one varying parameter;
- "Two-relations" (Figure 1d): variation in two parameters must be integrated to get the correct answer.



All the elements are the same



Form variation should be



1c. One-relation matrix with "to be inhibited" false neutral response (1R Neu) response (1R_Inhib) integrated to get the right answer



1e. Two-relations matrix with "to be inhibited" false response (2R_Inhib)

Example of the 5 conditions included in the task (from Curie et al., 2016)

1d. Two-relations matrix with neutral

response (2R_Neu).

Form and size variation should be integrated to get the right answer

Furthermore, false-responses of two different types exist: a "neutral" response, which is a choice different from the items displayed in the matrix (Figure 1b and 1d) and a "to be inhibited" response, which is identical to one of the matrix items displayed (Figure 1c and 1e). Thus, this task combines 5 different conditions: identical matrices (Id), one-relation matrices with neutral responses (1R_Neu), onerelation matrices with to be inhibited responses (1R_Inhib), two-relations matrices with neutral responses (2R Neu) and two-relations matrices with to be inhibited responses (2R Inhib).

Task Description/data acquisition

The participants are asked to identify the missing element that completes a pattern. The stimuli are displayed on a computer screen. Participants are told to find the best answer to fill in the missing "piece". For the patients, immediate visual feedback via a happy or sad emoticon (in case of right or

wrong answer, respectively) is given during the training to make the task easier to understand. The paradigm will consist of four runs. Each matrix is preceded by a fixation cross. The subject then has to select the correct answer by pushing a button. The number of each type of condition will be counterbalanced on each run, producing the same number of right and left answers. For each type of matrix, the type of variable relation (form, color, size, number) will also be counterbalanced. The order of different conditions in the matrix display will be randomized, as is the side of the correct answer. sε Jeresenta Joo runs. Each run consists of 45 trials in the behavioral task and 15 trials in the eyetracking task. The matrices are generated and displayed using Presentation software (http://www.neurobs.com). A break will be allowed if necessary between two runs.

Propriété du CHU Dijon Bourgogne